

**From:** Fauci, Anthony (NIH/NIAID) [E]  
**Sent:** Mon, 24 Feb 2020 02:00:10 +0000  
**To:** Myles, Renate (NIH/OD) [E]  
**Subject:** RE: FOR YOUR REVIEW: Draft Rollout, All Staff, and Statement on Preparing for Potential Patients w/ COVID-19

(b) (5) Thanks.

---

**From:** Myles, Renate (NIH/OD) [E] <(b) (6)>  
**Sent:** Sunday, February 23, 2020 8:56 PM  
**To:** Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>; Collins, Francis (NIH/OD) [E] <(b) (6)>; Tabak, Lawrence (NIH/OD) [E] <(b) (6)>; Gilman, James (NIH/CC/OD) [E] <(b) (6)>  
**Cc:** Burklow, John (NIH/OD) [E] <(b) (6)>; Hallett, Adrienne (NIH/OD) [E] <(b) (6)>; Allen-Gifford, Patrice (NIH/OD) [E] <(b) (6)>; Billet, Courtney (NIH/NIAID) [E] <(b) (6)>; Davey, Richard (NIH/NIAID) [E] <(b) (6)>; Palmore, Tara (NIH/CC/OD) [E] <(b) (6)>; Cohen, Justin (NIH/CC/OD) [E] <(b) (6)>  
**Subject:** RE: FOR YOUR REVIEW: Draft Rollout, All Staff, and Statement on Preparing for Potential Patients w/ COVID-19

Thanks, all. (b) (5)

Latest rollout, all staff and statement are attached.

Best,  
Renate

---

**From:** Fauci, Anthony (NIH/NIAID) [E] <[afauci@niaid.nih.gov](mailto:afauci@niaid.nih.gov)>  
**Sent:** Sunday, February 23, 2020 8:15 PM  
**To:** Myles, Renate (NIH/OD) [E] <[mylesr@mail.nih.gov](mailto:mylesr@mail.nih.gov)>; Collins, Francis (NIH/OD) [E] <[collinsf@od.nih.gov](mailto:collinsf@od.nih.gov)>; Tabak, Lawrence (NIH/OD) [E] <[lawrence.tabak@nih.gov](mailto:lawrence.tabak@nih.gov)>; Gilman, James (NIH/CC/OD) [E] <[james.gilman@nih.gov](mailto:james.gilman@nih.gov)>  
**Cc:** Burklow, John (NIH/OD) [E] <[burklowj@od.nih.gov](mailto:burklowj@od.nih.gov)>; Hallett, Adrienne (NIH/OD) [E] <[adrienne.hallett@nih.gov](mailto:adrienne.hallett@nih.gov)>; Allen-Gifford, Patrice (NIH/OD) [E] <[patrice.allen-gifford@nih.gov](mailto:patrice.allen-gifford@nih.gov)>; Billet, Courtney (NIH/NIAID) [E] <[billetec@niaid.nih.gov](mailto:billetec@niaid.nih.gov)>; Davey, Richard (NIH/NIAID) [E] <[rdavey@niaid.nih.gov](mailto:rdavey@niaid.nih.gov)>; Palmore, Tara (NIH/CC/OD) [E] <[tpalmore@cc.nih.gov](mailto:tpalmore@cc.nih.gov)>; Cohen, Justin (NIH/CC/OD) [E] <[justin.cohen@nih.gov](mailto:justin.cohen@nih.gov)>  
**Subject:** RE: FOR YOUR REVIEW: Draft Rollout, All Staff, and Statement on Preparing for Potential Patients w/ COVID-19

Renate:

The rollout plan looks fine except that I would include (b) (6)

Thanks,

Tony

---

**From:** Myles, Renate (NIH/OD) [E] (b) (6)>  
**Sent:** Sunday, February 23, 2020 7:23 PM  
**To:** Collins, Francis (NIH/OD) [E] (b) (6); Tabak, Lawrence (NIH/OD) [E] (b) (6)>; Fauci, Anthony (NIH/NIAID) [E] (b) (6)>; Gilman, James (NIH/CC/OD) [E] (b) (6)>  
**Cc:** Burklow, John (NIH/OD) [E] <(b) (6)>; Hallett, Adrienne (NIH/OD) [E] (b) (6)>; Allen-Gifford, Patrice (NIH/OD) [E] (b) (6); Billet, Courtney (NIH/NIAID) [E] (b) (6); Davey, Richard (NIH/NIAID) [E] (b) (6); Palmore, Tara (NIH/CC/OD) [E] (b) (6)>; Cohen, Justin (NIH/CC/OD) [E] (b) (6)>  
**Subject:** FOR YOUR REVIEW: Draft Rollout, All Staff, and Statement on Preparing for Potential Patients w/ COVID-19  
**Importance:** High

Good evening:

Attached for your review are draft materials to communicate NIH's preparation for potential receipt of patients with COVID-19 to the NIH Clinical Center (timing TBD), including:

1. Rollout plan
2. All staff email
3. Statement

These materials were reviewed by Rick Davey, Tara Palmore, and Courtney Billet. I am developing a list of potential Qs and will work with CC and NIAID folks to develop responses, but I wanted to get these products into review in the interest of time.

Best,  
Renate

Renate Myles, MBA  
Deputy Director for Public Affairs  
Office of Communications and Public Liaison  
National Institutes of Health  
Tel: (b) (6)

**From:** Fauci, Anthony (NIH/NIAID) [E]  
**Sent:** Sun, 23 Feb 2020 23:14:18 +0000  
**To:** Cassetti, Cristina (NIH/NIAID) [E]  
**Subject:** FW: Important regarding CoronaVirus

Please handle.

**From:** [REDACTED] (b) (6) >  
**Sent:** Sunday, February 23, 2020 6:10 PM  
**To:** Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6) >; Fauci, Anthony (NIH/NIAID) [E]  
[REDACTED] (b) (6)  
**Subject:** Important regarding CoronaVirus

Respected Dr. Anthony

It was great to know about you and your institution, for efforts in combating any emerging infectious disease.

I am writing this email regarding our preliminary observation about the coronavirus genome.

I wish to share with you we have found 12 mirror DNA sequence within the genome of Coronavirus. We have named it (MR1 to MR12). We are highly interested in MR2 as this mirror DNA sequence is absent in the human genome. [REDACTED] (b) (4)

I wish to add here there are few studies which state that mirror DNA has the potentiality to form H-DNA and later has a potentiality to induce mutations. We strongly believe a future study on mirror DNA can answer " Why some virus mutates faster ?" "Can we stop them from mutating? [REDACTED] (b) (4)

[REDACTED] (b) (4)  
[REDACTED] I will be thankful to you, if you can give me your valuable time to discuss telephonically or through skype our ideas. I can be reached at [REDACTED] (b) (6) .

I look forward to hearing from you.

with regards and Best wishes

Dr Vikash Bhardwaj (PhD JNU India)  
Asst Professor Biotechnology  
Starex University Gurugram India.



**From:** Fauci, Anthony (NIH/NIAID) [E]  
**Sent:** Sun, 23 Feb 2020 23:11:59 +0000  
**To:** Lerner, Andrea (NIH/NIAID) [E]  
**Cc:** Conrad, Patricia (NIH/NIAID) [E]  
**Subject:** RE: COVID-19 clinical care team

I am totally aware of all of this and have been directly involved in setting it up. You have my OK to participate to the extent that you desire.

-----Original Message-----

From: Lerner, Andrea (NIH/NIAID) [E] <[REDACTED]> (b) (6)>  
Sent: Sunday, February 23, 2020 5:39 PM  
To: Fauci, Anthony (NIH/NIAID) [E] <[REDACTED]> (b) (6)>  
Subject: COVID-19 clinical care team

Dear Dr. Fauci,

I got a call a few minutes ago from Veronique Nussenblatt, Chief of the Clinical Center ID Consult Service, regarding me being a part of the clinical care team of COVID-19 patients if they come to the NIH.

She did not have any definitive information but said there was a chance patients could be coming from California this week— this is the first I had heard of that, and I'm guessing you may know more about it than I do.

The work would include either day or night shifts, likely a couple a week. People on the clinical care team are not instructed to separate themselves from others and will be pcr tested for the virus daily when working clinically.

I wanted to ask for your OK to do this clinical work— of course I will maintain my responsibilities in the office while doing so. Please let me know and happy to discuss further if you'd like.

Sincerely,  
Andrea

Sent from my iPhone



**From:** Fauci, Anthony (NIH/NIAID) [E]  
**Sent:** Sun, 23 Feb 2020 21:35:02 +0000  
**To:** Haskins, Melinda (NIH/NIAID) [E]; Selgrade, Sara (NIH/NIAID) [E]; Crawford, Chase (NIH/NIAID) [E]  
**Cc:** Marston, Hilary (NIH/NIAID) [E]; Eisinger, Robert (NIH/NIAID) [E]; Lerner, Andrea (NIH/NIAID) [E]; Conrad, Patricia (NIH/NIAID) [E]  
**Subject:** Flip Cards

I have gone over the Flip cards. I note that we have only 2 cards for Coronavirus. I want to have a separate flip folder for coronavirus with a full set of cards for the specific coronavirus hearings that are coming up. You should sit down with me and also work with Hilary to prepare this set of cards. They should contain all the current epi as well as the dollar numbers for the proposed supplemental budget that we are putting together – I will get asked about that and I have clearance from the department to talk about it. Also, I want a set of cards for what we are doing in the area of research, i.e. basic research (eg animal models, etc.), diagnostics, therapeutics (remdesivir trials in China, Japan, and Nebraska), and the whole menu of vaccines. In other words, I want an entire set of cards for coronavirus. That is what I am going to get asked in both the coronavirus hearings as well as in the NIH Appropriations hearings.

**Anthony S. Fauci, MD**  
**Director**  
**National Institute of Allergy and Infectious Diseases**  
**Building 31, Room 7A-03**  
**31 Center Drive, MSC 2520**  
**National Institutes of Health**  
**Bethesda, MD 20892-2520**  
**Phone:** (b) (6)  
**FAX: (301) 496-4409**  
**E-mail:** (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

**From:** Fauci, Anthony (NIH/NIAID) [E]  
**Sent:** Sun, 23 Feb 2020 21:22:40 +0000  
**To:** Jon LaPook  
**Subject:** RE: Coronavirus reality check

How about a pastrami sandwich on rye and a potato knish?

Anthony S. Fauci, MD  
Director  
National Institute of Allergy and Infectious Diseases  
Building 31, Room 7A-03  
31 Center Drive, MSC 2520  
National Institutes of Health  
Bethesda, MD 20892-2520  
Phone: (b) (6)  
FAX: (301) 496-4409  
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

-----Original Message-----

From: Jon LaPook (b) (6)  
Sent: Sunday, February 23, 2020 4:16 PM  
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>  
Subject: Re: Coronavirus reality check

Thanks, Tony.

I would love you to consider my request to "tag along" with you some day - not to join you for meetings (I would wait outside unless invited in) or listen in on conference calls but to chat with you in between to give people an inside look at how seriously the government is taking the outbreak. And I could bring down a shmeat from Barney Greengrass for lunch. How could you pass that up???

Jon

Jonathan LaPook, M.D.  
Chief Medical Correspondent, CBS News  
Professor of Medicine  
NYU Langone Health  
Twitter @DrLaPook

On Feb 23, 2020, at 4:05 PM, Fauci, Anthony (NIH/NIAID) [E] (b) (6) > wrote:

Jon:

The current appearance of community transmissions in Japan, South Korea, Italy and Iran is troublesome. As I have repeatedly said over the past couple of weeks, if and when (looks more like when now) a number of other countries besides China have sustained human to human transmissions, then we will be on the brink of a pandemic,

if not already there. The reason to say this is that when several countries have widespread transmissions, then spill-over to other countries is inevitable since one cannot shut out the rest of the world and so you can expect increasing world-wide transmissions among progressively more countries. In essence, you will be experiencing a pandemic. We are not quite there yet, but we are getting disturbingly close. It will soon be a matter of semantics regarding who would be willing to call it since it is not a mathematically precise definition. I am not so sure that WHO will have the will to declare this a "pandemic" before a number of respected epidemiologists around the world start referring publicly to it as a pandemic regardless of what WHO does or does not declare. WHO will likely be behind the curve here and will wait until it is patently obvious what we are dealing with.

Hope that this is helpful.

Best,

Tony

Anthony S. Fauci, MD

Director

National Institute of Allergy and Infectious Diseases

Building 31, Room 7A-03

31 Center Drive, MSC 2520

National Institutes of Health

Bethesda, MD 20892-2520

Phone: (b) (6)

FAX: (301) 496-4409

E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

-----Original Message-----

From: Jon LaPook (b) (6)  
Sent: Sunday, February 23, 2020 3:47 PM  
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>  
Subject: Coronavirus reality check

Hi Tony,

Why do I not think that this is a relaxing Sunday for you?



This definitely feels like an inflection point in the coronavirus outbreak - both in the unsurprising way it's spreading and the equally unsurprising misinformation and public alarm/panic we are seeing. Unsurprising but here we are. Can you give me a quick brain dump on where you think we are and how I can best inform the public?

Thanks,

Jon

P.S. please let me know whenever I can report that the outbreak is officially being called a pandemic.

Jonathan LaPook, M.D.

Chief Medical Correspondent, CBS News

Professor of Medicine

NYU Langone Health

Twitter @DrLaPook

**From:** Fauci, Anthony (NIH/NIAID) [E]  
**Sent:** Sun, 23 Feb 2020 20:01:51 +0000  
**To:** Richard Allen Johnson  
**Subject:** RE: 2020.02.23 Sunday

Dick:

Transmission is definitely by respiratory droplet. Still unclear about aerosol transmission although there are anecdotal reports that this occurs similar to what we saw in individual episodes with SARS back in 2002-2003. Almost certainly contact transmission occurs with hand to mucosa (mouth, eyes, nasal mucosa). Unclear about fomites, doorknobs, etc. Virus can live for a couple of hours on certain inanimate objects. Virus definitely isolated from stool and urine, but not sure of role in transmission. No information about Transmission to fetus. Children have very low rate of infection. No good serologic test at this point although they are rapidly being developed.

Best,  
Tony

**Anthony S. Fauci, MD**  
**Director**  
**National Institute of Allergy and Infectious Diseases**  
**Building 31, Room 7A-03**  
**31 Center Drive, MSC 2520**  
**National Institutes of Health**  
**Bethesda, MD 20892-2520**  
**Phone:** (b) (6)  
**FAX:** (301) 496-4409  
**E-mail:** (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

**From:** Richard Allen Johnson (b) (6) >  
**Sent:** Sunday, February 23, 2020 2:32 PM  
**To:** Fauci, Anthony (NIH/NIAID) [E] (b) (6) >; Richard Allen Johnson (b) (6) >  
**Subject:** Re: 2020.02.23 Sunday

Thanks, Tony. Please continue communication with me by email. But rest your voice for a short while.

I am having trouble understanding the exact mode of transmission of COVID-19.

- Sneeze or cough produces respiratory droplet or aerosolized respiratory secretion which make contact with upper or lower respiratory mucosa, which results in infection of human cells. Seems most likely.
- What about contact transmission, contaminated hand to conjunctivae, nasal mucosa, or mouth
- Fecal/oral
- transmission to fetus
- What are the diagnostic tests to confirm diagnosis of novel coronavirus? PCR of secretions? Who in the world has these test kit; who manufactures kit.
- Are follow up serologies begin done?

Interesting questions to us and to Shelly Wolf if he were with us.

Thanks, Tony. My voice is also a little raspy.

Best,  
Dick

On Sun, Feb 23, 2020 at 10:46 AM Fauci, Anthony (NIH/NIAID) [E] <[REDACTED] (b) (6)> wrote:

Dick:

My voice is hoarse since I have been giving so many Congressional and White House briefings and TV and radio interviews. I just need to shut up for a while.

Best,  
Tony

**From:** Richard Allen Johnson [REDACTED] (b) (6)  
**Sent:** Sunday, February 23, 2020 5:25 AM  
**To:** Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6)>  
**Subject:** 2020.02.23 Sunday

Hi, Tony

I continue to follow the Cobid-19 epidemic.

What is the problem with your voice. It crackles like mine. I attribute mine to 'postnasal drip.'

WHO and Dr. Tedros are looking much better on TV. He has the WHO logo in the background. His tie show be tighter. His slouch is better. He still puts his elbows on the table in front of him.

Looking forward to lunch with you.

Best,  
Dick



**From:** Fauci, Anthony (NIH/NIAID) [E]  
**Sent:** Sun, 23 Feb 2020 15:56:48 +0000  
**To:** Margolis, Leonid (NIH/NICHHD) [E]  
**Cc:** Cassetti, Cristina (NIH/NIAID) [E];Erbelding, Emily (NIH/NIAID) [E];Conrad, Patricia (NIH/NIAID) [E]  
**Subject:** RE: Coronavirus tissue test system: a suggestion

Thanks, Leonid. I will pass this on to appropriate associates.  
Best regards,  
Tony

---

**From:** Margolis, Leonid (NIH/NICHHD) [E] (b) (6) >  
**Sent:** Sunday, February 23, 2020 5:50 AM  
**To:** Fauci, Anthony (NIH/NIAID) [E] (b) (6)  
**Subject:** Coronavirus tissue test system: a suggestion  
**Importance:** High

Dear Tony,

As you may know, for many years we study HIV pathogenesis in human tissues *ex vivo*. (Among my many papers, there is one, may be not the best, but that I am most proud of. This is where my co-author is Dr. Fauci 😊)

(b) (5)

Regards,  
Leonid

Leonid Margolis, Ph.D.  
Head,  
Section of Intercellular Interactions  
Eunice Kennedy-Shriver National Institute of Child Health and Human Development  
Building 29B, Room 1H16D  
29 Lincoln Drive  
Bethesda, MD 20892  
Phone: (b) (6)  
Fax: 301-480-0857  
e-mail: (b) (6)

**From:** Fauci, Anthony (NIH/NIAID) [E]  
**Sent:** Sun, 23 Feb 2020 15:53:48 +0000  
**To:** john won  
**Subject:** RE: KAMA

John:

Thank you very much for your kind note. I hope that all is well with you.

Best regards,

Tony

---

**From:** john won [REDACTED] (b) (6) >  
**Sent:** Sunday, February 23, 2020 9:06 AM  
**To:** Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6) >  
**Subject:** Re: KAMA

Dear Dr. Fauci,

I hope you are doing well. Your participation during our Washington DC 2017 convention was one of the most memorable events of our organization's history.

United States and the world now turns to you for your help as Coronavirus crisis is becoming pandemic. All of us here at KAMA are thinking about you and all those affected. Thank you very much for all your contributions.

Warm regards,

John Won

On Oct 24, 2017, at 10:42 AM, Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6) wrote:

John:

Thank you for your kind note. It was a pleasure to be with you.

Best regards,

Tony

**From:** john won [REDACTED] (b) (6)  
**Sent:** Tuesday, October 24, 2017 10:12 AM  
**To:** Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6) >  
**Subject:** KAMA

Dear Dr. Fauci,

Thank you very much for speaking to us at the 43rd Annual KAMA Convention. It was a tremendous privilege for all of us. You were also so kind to stay afterwards to take pictures with all those who asked.

To be honest, having you there was very surreal. You symbolize the best of American medicine. I grew up idolizing your accomplishments as college and medical student. You saved and touched the lives of so many around the world. It is still hard to believe that I had this special opportunity to welcome you.

We will continue to do our best to serve the public and mentor medical students. I hope you can speak to us again in the near future. Thank you very much. I hope you continue in your position for another 40 years.

Warmest regards,

John H. Won



**From:** Fauci, Anthony (NIH/NIAID) [E]  
**Sent:** Sun, 23 Feb 2020 15:52:06 +0000  
**To:** Julia Belluz  
**Subject:** RE: Comment?

Julia:

The appearance of community transmissions in Japan, South Korea, Italy and Iran is troublesome. As I have repeatedly said over the past couple of weeks, if and when (looks more like when now) a number of other countries besides China have sustained human to human transmissions, then we are on the brink of a pandemic, if not already there. The reason to say this is that when several countries have widespread transmission, then spill-over to other countries is inevitable since one cannot shut out the rest of the world and so you can expect increasing world-wide transmissions. Hence, you will be experiencing a pandemic. We are not quite there yet, but we are getting disturbingly close.

I hope that this is helpful.

Best,  
Tony

---

**From:** Julia Belluz <julia.belluz@vox.com>  
**Sent:** Sunday, February 23, 2020 4:13 AM  
**To:** Fauci, Anthony (NIH/NIAID) [E] (b) (6)>  
**Cc:** julia.belluz@voxmedia.com; Conrad, Patricia (NIH/NIAID) [E] (b) (6)>; Barasch, Kimberly (NIH/NIAID) [C] (b) (6)  
**Subject:** Comment?

Dear Dr. Fauci,

Just over a week ago we talked for this story about how the outbreak is likely larger than we know now:

<https://www.google.com/amp/s/www.vox.com/platform/amp/2020/2/14/21134473/coronavirus-outbreak-singapore-us-symptoms-pandemic>

Given the developments in Singapore, Iran, Italy, and on the Diamond Princess cruise ship, I'm just wondering how your opinion about the possibility of containment and how fast we are approaching a pandemic has changed. Do these developments suggest we've entered a new phase in the outbreak?

If you have a few minutes to chat or email today, let me know. We'll be aiming to run a story on this today.

Thank you for considering.

Julia

On Feb 15, 2020, at 12:10 AM, Julia Belluz <[julia.belluz@vox.com](mailto:julia.belluz@vox.com)> wrote:

Thank you so much for making the time to comment at what I know is a crushingly busy time. As usual don't hesitate to ping if you have any further comments or questions! Julia

<https://www.vox.com/2020/2/14/21134473/coronavirus-outbreak-singapore-us-symptoms-pandemic>

Sent from my iPhone

On Feb 14, 2020, at 1:21 PM, Fauci, Anthony (NIH/NIAID) [E]

(b) (6) wrote:

Julia:

I just called you now (7:20 AM Washington, DC time) and got mvoice mail in German that I could not understand. You can call me at (b) (6).

Thanks,

Tony

Anthony S. Fauci, MD

Director

National Institute of Allergy and Infectious Diseases

Building 31, Room 7A-03

31 Center Drive, MSC 2520

National Institutes of Health

Bethesda, MD 20892-2520

Phone: (b) (6)

FAX: (301) 496-4409

E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

**From:** Fauci, Anthony (NIH/NIAID) [E]  
**Sent:** Sun, 23 Feb 2020 14:26:22 +0000  
**To:** Theodore Li  
**Subject:** RE: Covid-19 question

Ted:

Thanks for the note. Since she is 22 days out of Singapore she would be well beyond the 14 day quarantine used for people who are coming out of risk zones. And so although her risk is never zero, it is really very low. If she were coming from Japan or South Korea, which are experiencing an emerging outbreak, I might feel a little different, but Singapore has good infection control despite the number of cases in that country. Given her history of recent Shingrix vaccination, I would wait another day to see if her fever breaks. I agree that I would keep her at home for now. I do not think it would come to that, but if you want to get testing done, it still would have to go to the CDC via the Virginia department of health. Bottom line is that I would sit tight for now and see how she does over the next day or so. If things change, do not hesitate to call or e-mail me.

Best,  
Tony

---

**From:** Theodore Li [REDACTED] (b) (6)>  
**Sent:** Sunday, February 23, 2020 9:11 AM  
**To:** Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6)  
**Subject:** Covid-19 question

Hi Tony,

The wife of one of my patients received the Shingrix vaccine on Thursday 2/20 and developed fever to 101.4 the following day with malaise, headache, mild nausea (no respiratory symptoms). She's taken ibuprofen with transient temperature reduction; the fever and symptoms are the same today.

BUT . . . she and her daughter were in Singapore [REDACTED] (b) (6) where they stayed at the [REDACTED] (b) (6), visited [REDACTED] (b) (6) and the [REDACTED] (b) (6). They then flew to Colombo, Sri Lanka before returning via Europe last [REDACTED] (b) (6) to [REDACTED] (b) (6). So her fever began 3 weeks plus 1 day after being in Singapore.

I've told her to keep treating the fever and symptoms but to stay at home for now. The fever after Shingrix usually resolves after 2-3 days so I'd expect it to abate today or tomorrow. My question is whether there's enough of a concern, viz. the time in Singapore, for her to be tested for covid-19. If so, what's the best way to conduct the testing? Or is it okay to see if her fever breaks by tomorrow?

(You must be getting lots of these questions).

Best,  
Ted



**From:** Fauci, Anthony (NIH/NIAID) [E]  
**Sent:** Sun, 23 Feb 2020 04:27:10 +0000  
**To:** Tabak, Lawrence (NIH/OD) [E]  
**Cc:** Collins, Francis (NIH/OD) [E] (b) (6); Conrad, Patricia (NIH/NIAID) [E]  
**Subject:** Heads Up

Larry:

I need to speak with you tomorrow (Sunday) about a request that we (NIH) will get from ASPR (Kadlec) regarding the housing of asymptomatic coronavirus positive individuals. I am copying Francis since the discussion will ultimately get to him.

Best,  
Tony

**Anthony S. Fauci, MD**  
Director  
National Institute of Allergy and Infectious Diseases  
Building 31, Room 7A-03  
31 Center Drive, MSC 2520  
National Institutes of Health  
Bethesda, MD 20892-2520  
Phone: (b) (6)  
FAX: (301) 496-4409  
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

**From:** Fauci, Anthony (NIH/NIAID) [E]  
**Sent:** Sat, 22 Feb 2020 21:06:45 +0000  
**To:** Cassetti, Cristina (NIH/NIAID) [E]  
**Subject:** FW: Coronavirus

Please handle. Thanks.

**Anthony S. Fauci, MD**  
Director  
National Institute of Allergy and Infectious Diseases  
Building 31, Room 7A-03  
31 Center Drive, MSC 2520  
National Institutes of Health  
Bethesda, MD 20892-2520  
Phone: (b) (6)  
FAX: (301) 496-4409  
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

**From:** OB Roberts (b) (6) >  
**Sent:** Saturday, February 22, 2020 4:03 PM  
**To:** Fauci, Anthony (NIH/NIAID) [E] (b) (6) >  
**Subject:** Coronavirus

To: Dr. Fauci

FM: Oliver B Roberts

(b) (6)

Dr. Fauci; I attended a small water seminar, put on by local (Seventh Day Adventist) medical professionals, in the mid 1970's at Elms Haven, California.

This seminar taught the participants how to eliminate the flu with the use of water treatments, ie (steam baths, etc).

I have now for these past 40 some-odd years, been taking two treatment's; one in the evening and another in the middle of the night, whenever I have contacted the flu: AND have had the facilities to do so; and each time I was well the next morning. No temperature, no symptoms whatsoever.

With the high rate that this Coronavirus is spreading, one can see what a great tool these treatments can be for medical professionals. To have those who are sick with the flu, completely free of all symptoms after two treatments would greatly ease the burden on Dr's and other medical professionals AND each facility.

Dr. I am asking for a few minutes of your time to explain this. I would like to share this with you and others. I just want to help by sharing what I learned and have been doing all these years. I feel so guilty, knowing this and not having a way to get this information to those needing it, when there so many out there sick and dying.

Note: I have been trying to reach out, hoping someone will hear me. Alas I do not have the education, pedigree nor the contacts: But you Dr. have all three! I ask not that you believe in me, but that you believe in these treatments.

Thank You for your time, please feel free to contact me via email or by phone or text or even have someone up here talk with me.

Sincerely;

OB Roberts  
(Ben)



**From:** Fauci, Anthony (NIH/NIAID) [E]  
**Sent:** Sat, 22 Feb 2020 21:04:58 +0000  
**To:** Conrad, Patricia (NIH/NIAID) [E]  
**Cc:** Barasch, Kimberly (NIH/NIAID) [C]  
**Subject:** FW: Congratulations and time to speak: Researchers Are Racing to Make a Coronavirus Vaccine. Will It Help? - The New York Times

Please set up a call with Hannah

Anthony S. Fauci, MD  
Director  
National Institute of Allergy and Infectious Diseases  
Building 31, Room 7A-03  
31 Center Drive, MSC 2520  
National Institutes of Health  
Bethesda, MD 20892-2520  
Phone: (b) (6)  
FAX: (301) 496-4409  
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

---

**From:** Valantine, Hannah (NIH/OD) [E] (b) (6)  
**Sent:** Tuesday, February 18, 2020 10:05 AM  
**To:** Fauci, Anthony (NIH/NIAID) [E] (b) (6)  
**Subject:** Congratulations and time to speak: Researchers Are Racing to Make a Coronavirus Vaccine. Will It Help? - The New York Times  
**Importance:** High

Hi Tony,

I have been following this terrific work by NIAID scientists in the VRC – congratulations!

<https://www.nytimes.com/2020/01/28/health/coronavirus-vaccine.html>

As you can imagine I am delighted see Dr. Kizzmekia Corbett playing a leading role in these activities. Most importantly she is delighted with the mentorship, sponsorship and opportunity she has received at NIH, particularly from Barney Graham. (b) (6), (b) (5)

Please let me know when you might be available to speak with me.

Best,  
Hannah



**From:** Fauci, Anthony (NIH/NIAID) [E]  
**Sent:** Sat, 22 Feb 2020 20:53:35 +0000  
**To:** NIAID OD AM  
**Subject:** FW: CUGH Annual Meeting

Let bus discuss.

**Anthony S. Fauci, MD**  
Director  
National Institute of Allergy and Infectious Diseases  
Building 31, Room 7A-03  
31 Center Drive, MSC 2520  
National Institutes of Health  
Bethesda, MD 20892-2520  
Phone: (b) (6)  
FAX: (301) 496-4409  
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

---

**From:** Thomas Quinn (b) (6)  
**Sent:** Thursday, February 20, 2020 3:56 PM  
**To:** Fauci, Anthony (NIH/NIAID) [E] (b) (6)>  
**Cc:** Folkers, Greg (NIH/NIAID) [E] (b) (6); Conrad, Patricia (NIH/NIAID) [E] (b) (6)>; Barasch, Kimberly (NIH/NIAID) [C] (b) (6)>; Judith Wasserheit (b) (6)>  
**Subject:** CUGH Annual Meeting

Hi Tony,

I know how busy you are but I wanted to give you a brief update on the Annual Conference of the Consortium of Universities for Global Health (CUGH) based in Washington, DC. Here is the link to the overall CUGH meeting which provides an overview of the whole conference <https://www.cugh2020.org/program>. As we discussed months ago you agreed to be in the opening day plenary session on April 18<sup>th</sup>, entitled "Emerging Infectious Diseases and their Impact on Global Health Security". **The details and other speakers are listed below.** I may try to organize a call of all speakers in a month to coordinate talks/topics as the session is 90 minutes with 5 speakers, and a lot of ground to cover, especially with the COVID19 outbreak.

Judy Wasserheit, copied here, would also like to invite you to a special session she is organizing on the coronavirus epidemic at the same CUGH conference in a late-breaker session on Sunday, April 19 (the second day of the conference) from 8:45am-10:15am at the Washington Hilton Hotel (Monroe Room). This talk would be slightly different from the plenary session and you could expand on **COVID19 research priorities and update on progress**. We realize your schedule is very busy but your insights and knowledge on both of these topics is unparalleled. If you cannot speak at the second session we would appreciate your recommendation as to an alternative who could address this latter topic.

Thanks and all the best,  
Tom

### **Plenary Session Details:**

**Session Day:** Saturday, April 18, 2020

**Session Time:** 11:30am-1:00pm

**Location:** Washington Hilton Hotel, International Ballroom

**Panel Title:** "Emerging Infectious Diseases and their Impact on Global Health Security"

**Short Panel Description:** This Plenary Panel will highlight the continual threats of emerging and re-emerging infectious diseases, and their impact on global security for surveillance, detection, treatment and prevention of these diseases. Over recent decades, multiple epidemic events have underscored how highly vulnerable we are to viral threats. Our world is globally connected—and an "emerging threat" in one part of the world can pose a threat everywhere and to everyone. About 75 percent of new human diseases are caused by microbes that originate in animals. These include HIV, influenza (including pandemic H1N1, H5N1, and H7N9), Severe Acute Respiratory Syndrome (SARS), Middle East Respiratory Syndrome-Coronavirus (MERS-CoV), Ebola, Marburg, and Nipah. The recent emergence of COVID from China clearly illustrates the magnitude, rapidity

and impact that a new infectious agent can have on global health security. This panel of leading experts will discuss the emergence of these microbial threats, and our ability to detect, respond and prevent future epidemics of these pathogens.

**Moderator(s) Info:** Tom Quinn, Chief, NIAID, International HIV/STD Section and Man Charurat, Director, Division of Epidemiology and Prevention, Institute of Human Virology (IHV)

**Speaker(s) Info:**

**1. Anthony Fauci, Director, NIAID**

**2. Chikwe Ihekweazu, Director General, Nigeria CDC**

**3. Peter Hotez, Dean, National School of Tropical Medicine, Baylor College of Medicine**

**4. Jonna Mazet, Executive Director, One Health Institute, and PI, PREDICT project, UC Davis**

**5. Jennifer Nuzzo, Senior Scholar, Center for Health Security, Johns Hopkins University**

**From:** Fauci, Anthony (NIH/NIAID) [E]  
**Sent:** Sat, 22 Feb 2020 20:51:00 +0000  
**To:** Stover, Kathy (NIH/NIAID) [E]  
**Cc:** Billet, Courtney (NIH/NIAID) [E]; Conrad, Patricia (NIH/NIAID) [E]; Folkers, Greg (NIH/NIAID) [E]  
**Subject:** RE: FOR ASF REVIEW: Draft PR re: launch of remdesivir COVID-19 trial  
**Attachments:** NIAID press release COVID-19 treatment trial FOG - with fauci tracked edits.docx

See my minor tracked edits. Thanks.

Anthony S. Fauci, MD  
Director  
National Institute of Allergy and Infectious Diseases  
Building 31, Room 7A-03  
31 Center Drive, MSC 2520  
National Institutes of Health  
Bethesda, MD 20892-2520  
Phone: (b) (6)  
FAX: (301) 496-4409  
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

---

**From:** Stover, Kathy (NIH/NIAID) [E] (b) (6)  
**Sent:** Friday, February 21, 2020 3:55 PM  
**To:** Fauci, Anthony (NIH/NIAID) [E] (b) (6)>  
**Cc:** Billet, Courtney (NIH/NIAID) [E] (b) (6); Conrad, Patricia (NIH/NIAID) [E] (b) (6)>; Folkers, Greg (NIH/NIAID) [E] (b) (6)>  
**Subject:** FOR ASF REVIEW: Draft PR re: launch of remdesivir COVID-19 trial

Hi Dr. Fauci,

Please find attached for your review a draft press release to announce the launch of the remdesivir COVID-19 treatment trial, which enrolled its first patient today. It's been reviewed by the following individuals/groups:

- FOG
- OCGR (Kathy Stover, Courtney Billet)
- DMID: Emily Erbelding, John Beigel
- DCR: Cliff Lane, Libby Higgs
- U Nebraska (Christopher Kratochvil, Andre Kalil, comms dept)
- Awaiting comments from Gilead and WHO.



For ease of reference, the following is the quote we have drafted for your use:



Thanks much,  
Kathy

Kathy Stover  
Branch Chief  
News and Science Writing Branch  
Office of Communications and Government Relations  
National Institute of Allergy and Infectious Diseases  
National Institutes of Health  
31 Center Drive, Room 7A17F  
Bethesda, MD 20892

(b) (6)  
Media line: (301) 402-1663

**From:** Fauci, Anthony (NIH/NIAID) [E]  
**Sent:** Sat, 22 Feb 2020 20:38:12 +0000  
**To:** Conrad, Patricia (NIH/NIAID) [E]  
**Cc:** Routh, Jennifer (NIH/NIAID) [E]  
**Subject:** RE: interview request: draft responses for Greek newspaper

Good job! See my minor edits in **red**. Thanks.

**Anthony S. Fauci, MD**  
Director  
National Institute of Allergy and Infectious Diseases  
Building 31, Room 7A-03  
31 Center Drive, MSC 2520  
National Institutes of Health  
Bethesda, MD 20892-2520  
Phone: (b) (6)  
FAX: (301) 496-4409  
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

---

**From:** Conrad, Patricia (NIH/NIAID) [E] (b) (6)  
**Sent:** Friday, February 21, 2020 4:57 PM  
**To:** Fauci, Anthony (NIH/NIAID) [E] (b) (6)  
**Subject:** FW: interview request: draft responses for Greek newspaper

Do you want to edit these..greek paper/pring?

Patricia L. Conrad  
Public Health Analyst and  
Special Assistant to the Director  
National Institute of Allergy and Infectious Diseases  
The National Institutes of Health  
31 Center Drive, MSC 2520 - Room 7A03  
Bethesda, Maryland 20892  
(b) (6)  
301-496-4409 fax

Disclaimer:

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it

from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statement made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

---

**From:** Routh, Jennifer (NIH/NIAID) [E] (b) (6)>  
**Sent:** Friday, February 21, 2020 4:52 PM  
**To:** Conrad, Patricia (NIH/NIAID) [E] (b) (6)>; NIAID FOG <[fog@niaid.nih.gov](mailto:fog@niaid.nih.gov)>  
**Cc:** NIAID COGCORE <[COGCORE@mail.nih.gov](mailto:COGCORE@mail.nih.gov)>; NIAID Media Inquiries <[mediainquiries@niaid.nih.gov](mailto:mediainquiries@niaid.nih.gov)>  
**Subject:** interview request: draft responses for Greek newspaper

Reporter: Theodora Tsoli  
Organization: Greek newspaper To VIMA ([www.tovima.gr](http://www.tovima.gr))  
Phone #(s): (b) (6), [ttsoli@tovima.gr](mailto:ttsoli@tovima.gr)  
Subject: COVID-19  
Deadline: Monday 2/24

The reporter emailed questions for ASF. I have drafted proposed responses for his review, also attached.

- 1. Do you believe that SARS-COV2 is capable of causing a pandemic? Are you expecting many secondary transmissions of the virus outside China?**  
A pandemic is generally defined as sustained transmission of a new pathogen in multiple regions of the world. COVID-19 does not yet meet that definition, and I hope that China and other countries in Asia with some transmission are able to contain the outbreak. However, it is possible that COVID-19 could become a pandemic. It would not be surprising to see additional secondary transmissions of the virus outside of China.
- 2. Chinese authorities are reporting a decline of new cases. Could we say that the virus has peaked and maybe it will slow down? When are you expecting to have a clearer picture about the evolution of this epidemic?**  
Although the number of **daily** cases in China appears to have gone down, it is too early to tell if this is really a decline in the outbreak.
- 3. Could the virus become endemic and give seasonal outbreaks?**  
If China is not able to contain the outbreak, it is possible COVID-19 could become endemic and lead to seasonal outbreaks. However, it is too early to know the likelihood of this scenario.
- 4. What about its transmissibility? Some experts say that WHO is underestimating it's transmissibility. Could the reality be different maybe because, among other things, many cases stay undetected?**  
Because of the many unknowns about SARS-CoV-2, it is difficult to make any firm conclusions regarding overall transmissibility and severity. However, it appears to be much more transmissible than SARS. Also, there are likely asymptomatic COVID-19 infections that are not getting counted because people do not go to the doctor for testing or treatment if they are not sick.



5. **Do you believe that the measures taken by China and countries around the world are adequate to stop SARS-COV2 spread? There is a lot of discussion about thermal cameras and travel restrictions for example.**  
China has taken extreme measures to control the outbreak. Restricting the movement of 50 million people is unprecedented. However, it might ultimately have an effect on slowing transmission. Precautions implemented in the U.S. are not intended to detect every person with COVID-19 entering the country. However, our approach has allowed us time to better plan and prepare our health system.
6. **What is the key to stop the worldwide spread of the virus?**  
Though we have mobilized a rapid research response to quickly develop effective countermeasures, right now, the outbreak response remains focused on the proven public health practices of identifying cases, isolating patients and tracing contacts.
7. **In the northern hemisphere we have a flu outbreak - in Greece as well. Some experts say that this is the real danger and not the coronavirus. What is your view?**  
I am always concerned about influenza. Every flu season, millions of people are at risk of getting very sick or dying. Currently people in the U.S. and most countries in the northern hemisphere are at a much higher risk of being exposed to influenza than SARS-CoV-2. However, the COVID-19 outbreak is an evolving situation and we are treating it as a very serious public health threat.
8. **Many efforts are being in process for the development of a vaccine for the new coronavirus. Are you coordinating any of them and which ones? Are there any efforts more promising than others? Which platforms of vaccine development are more promising? When do you believe that we could have a vaccine available for clinical trials and then for human use?**  
NIAID is exploring multiple candidates and is on track to test an experimental messenger RNA (mRNA) vaccine in a Phase 1 clinical trial this spring. This first phase of clinical testing will involve giving the vaccine to healthy adults in the United States to see if it is safe and if it can induce an immune response in recipients. It is important to realize that the development of investigational vaccines and the clinical testing to establish their safety and effectiveness takes time. A vaccine against the novel coronavirus will likely not be widely available for **more than** a year.
9. **What about therapies? Dozens are being tried - from plasma to herbal medicines in China. Which are the most promising?**  
NIAID is pursuing the development of antivirals and monoclonal antibodies for potential use against COVID-19. NIAID is preparing protocols for *in vitro* and *in vivo* studies of the antiviral remdesivir, which has shown promise against other coronaviruses in animal models. NIAID also plans to evaluate Kaletra (lopinavir/ritonavir) and interferon-beta for their activity against SARS-CoV-2. In addition, NIAID scientists are working to identify monoclonal antibodies with

therapeutic potential from stored SARS patient samples as well as COVID-19 patient samples.

10. **Are the things we know about this new virus more than the ones we don't know? Which are the main questions about it that remain to be answered?**  
New data **are** published about SARS-CoV-2 every day. However, we still have a lot to learn. For example, we do not know why there are **so few cases among** children, which is uncommon for a respiratory virus.
11. **How worried should people outside China be about SARS-COV2? What is the biggest danger from this virus?**  
. The risk to the general American public remains low at this time; **however, this could change and that is why we are treating the emergence of a novel coronavirus as a very serious public health threat.** We understand that people may be worried. We ask that people not let fear or panic guide their actions.
12. **Which are the protective measures anyone should take against the new virus? Do masks work?**  
The vast majority of people outside of China do not need to wear a mask. A mask is more appropriate for someone who is infected than for people trying to protect against infection.

Jennifer Routh [E]  
News and Science Writing Branch  
Office of Communications and Government Relations  
National Institute of Allergy and Infectious Diseases (NIAID)  
NIH/HHS  
31 Center Drive Room 7A17C  
Bethesda, MD 20892  
Direct: (b) (6)  
(b) (6)

**Disclaimer:** The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases shall not accept liability for any statements made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.



**From:** Fauci, Anthony (NIH/NIAID) [E]  
**Sent:** Sat, 22 Feb 2020 19:41:48 +0000  
**To:** Cassetti, Cristina (NIH/NIAID) [E]  
**Subject:** RE: HHS Engages Sanofi's Recombinant Technology for 2019 Novel Coronavirus Vaccine

Thanks.

**Anthony S. Fauci, MD**  
**Director**  
**National Institute of Allergy and Infectious Diseases**  
**Building 31, Room 7A-03**  
**31 Center Drive, MSC 2520**  
**National Institutes of Health**  
**Bethesda, MD 20892-2520**  
**Phone:** (b) (6)  
**FAX:** (301) 496-4409  
**E-mail:** (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

---

**From:** Cassetti, Cristina (NIH/NIAID) [E] (b) (6) >  
**Sent:** Saturday, February 22, 2020 2:26 PM  
**To:** Fauci, Anthony (NIH/NIAID) [E] (b) (6) >  
**Cc:** Erbeling, Emily (NIH/NIAID) [E] (b) (6) >  
**Subject:** Fwd: HHS Engages Sanofi's Recombinant Technology for 2019 Novel Coronavirus Vaccine

This is the press release from ASPR, in case you need more information on the Sanofi CoV efforts

Cristina

Begin forwarded message:

**From:** "Folkers, Greg (NIH/NIAID) [E]" (b) (6)  
**Date:** February 18, 2020 at 3:07:21 PM EST  
**Subject:** HHS Engages Sanofi's Recombinant Technology for 2019 Novel Coronavirus Vaccine

**FOR IMMEDIATE RELEASE**  
**February 18, 2020**  
**Contact: ASPR Press Office**  
**202-205-8117**  
[asprmedia@hhs.gov](mailto:asprmedia@hhs.gov)



# HHS Engages Sanofi's Recombinant Technology for 2019 Novel Coronavirus Vaccine

Racing to develop a vaccine against the 2019 novel coronavirus, the U.S. Department of Health and Human Services' Office of the Assistant Secretary for Preparedness and Response has engaged Sanofi Pasteur, the vaccines global business unit of Sanofi. The Biomedical Advanced Research and Development Authority (BARDA), a component of ASPR, will provide expertise and reallocated funds to support the vaccine's development. Sanofi will use its egg-free, recombinant DNA platform to produce a recombinant 2019 novel coronavirus vaccine candidate.

The technology produces an exact genetic match to proteins of the virus. The protein's DNA will be combined with DNA from a virus harmless to humans, and used to rapidly produce large quantities of antigen which stimulate the immune system to protect against the virus. The antigens will be separated and collected from these cells and purified to create working stocks of vaccine for advanced development.

"Flexibility and scalability are cornerstones of rapid response to an emerging infectious disease," said BARDA Director Rick A. Bright, Ph.D. "Using this proven technology, we can pivot immediately to address this new global health threat. Our goal is a licensed vaccine to provide long-term health security against this latest virus and prevent future coronavirus outbreaks."

BARDA has worked with Sanofi since 2004 and in 2009 began collaborating with Protein Sciences of Meridian, Connecticut, now owned by Sanofi, to develop a recombinant technology with the flexibility to make millions of doses of vaccine quickly in an influenza pandemic. In 2016, BARDA added this vaccine to the U.S. National Pre-pandemic Influenza Vaccine Stockpile. When Sanofi purchased the company and its technology in 2017, BARDA continued working with Sanofi on pandemic vaccine development, and in December 2019 the partners began focusing on increasing [manufacturing capacity](#) for recombinant influenza vaccine in the United States, in accordance with a [presidential executive order](#) to enhance national security and the public health by modernizing influenza vaccines and technologies.

This expanded collaboration with Sanofi is BARDA's second program to focus on developing a novel coronavirus vaccine candidate in the past few weeks. There is currently no approved vaccine, treatment, or diagnostic for novel coronavirus infections; however, the U.S. Food and Drug Administration has issued an emergency use authorization (EUA) to enable emergency use of a diagnostic test developed by the Centers for Disease Control and Prevention.

BARDA also is working with counterparts across the government, including within HHS and with the Department of Defense. The team is reviewing potential vaccines, treatments and diagnostics from across the public and private sectors, particularly products in development for Middle East Respiratory Syndrome (MERS) or Severe Acute Respiratory Syndrome (SARS), to identify promising candidates for development and licensure to detect, protect against or treat novel coronavirus infections.

To obtain information about any potential products in development in the private sector that could be used in responding to the novel coronavirus outbreak, the U.S. government

launched a single point-of-entry [website](#) for innovators and product developers to submit brief descriptions of their diagnostics, therapeutics, vaccines, and other products or technologies relevant to this new virus.

Federal agencies are particularly interested in identifying products and technologies that have progressed into or beyond non-clinical studies, have established large-scale commercial Good Manufacturing Practices (cGMP) manufacturing capability, and/or have utilized a platform already approved by the U.S. Food and Drug Administration (FDA). BARDA also opened an easy broad agency announcement, an [EZ-BAA](#), specific to diagnostics that utilize platforms already cleared by the FDA, with a viable plan to meet requirements for the FDA to consider Emergency Use Authorization (EUA) within 12 weeks of an award.

#### **About HHS, ASPR, and BARDA**

HHS works to enhance and protect the health and well-being of all Americans, providing for effective health and human services and fostering advances in medicine, public health, and social services. The mission of ASPR is to save lives and protect Americans from 21st century health security threats. Within ASPR, BARDA invests in innovation, advanced research and development, acquisition, and manufacturing of medical countermeasures – vaccines, drugs, therapeutics, diagnostic tools, and non-pharmaceutical products needed to combat health security threats. To date, 54 BARDA-supported products have achieved regulatory approval, licensure or clearance. BARDA DRIVE brings together the best ideas from the medical and scientific communities, together with government and venture capital investment, to drive innovation that will strengthen our nation's health security. To learn more about preparing for and responding to public health emergencies, from new infectious diseases to natural disasters and bioterrorism, by visiting the HHS public health emergency website, [www.phe.gov](http://www.phe.gov). For more information on partnering with BARDA on developing medical countermeasures, visit [www.medicalcountermeasures.gov](http://www.medicalcountermeasures.gov), and for more on DRIVE, visit [drive.hhs.gov](http://drive.hhs.gov).

###

Note: All HHS press releases, fact sheets and other news materials are available at <https://www.hhs.gov/news>.

Like [HHS on Facebook](#) , follow HHS on Twitter [@HHSgov](#) , and sign up for [HHS Email Updates](#).

Last revised: February 18, 2020

**Disclaimer: Any third-party material in this email has been shared for internal use under fair use provisions of U.S. copyright law, without further verification of its accuracy/veracity. It does not necessarily represent my views nor those of NIAID, NIH, HHS, or the U.S. government.**



**From:** Fauci, Anthony (NIH/NIAID) [E]  
**Sent:** Sat, 22 Feb 2020 19:41:42 +0000  
**To:** David Willman  
**Subject:** FW: HHS Engages Sanofi's Recombinant Technology for 2019 Novel Coronavirus Vaccine

David:

See press release below regarding BARDA and Sanofi.

Best,

Tony

Anthony S. Fauci, MD  
Director  
National Institute of Allergy and Infectious Diseases  
Building 31, Room 7A-03  
31 Center Drive, MSC 2520  
National Institutes of Health  
Bethesda, MD 20892-2520  
Phone: (b) (6)  
FAX: (301) 496-4409  
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

---

**From:** Cassetti, Cristina (NIH/NIAID) [E] (b) (6)  
**Sent:** Saturday, February 22, 2020 2:26 PM  
**To:** Fauci, Anthony (NIH/NIAID) [E] (b) (6) >  
**Cc:** Erbeling, Emily (NIH/NIAID) [E] (b) (6)  
**Subject:** Fwd: HHS Engages Sanofi's Recombinant Technology for 2019 Novel Coronavirus Vaccine

This is the press release from ASPR, in case you need more information on the Sanofi CoV efforts

Cristina

Begin forwarded message:

**From:** "Folkers, Greg (NIH/NIAID) [E]" (b) (6) >  
**Date:** February 18, 2020 at 3:07:21 PM EST  
**Subject:** HHS Engages Sanofi's Recombinant Technology for 2019 Novel Coronavirus Vaccine



FOR IMMEDIATE RELEASE  
February 18, 2020  
Contact: ASPR Press Office  
202-205-8117  
[asprmedia@hhs.gov](mailto:asprmedia@hhs.gov)

## HHS Engages Sanofi's Recombinant Technology for 2019 Novel Coronavirus Vaccine

Racing to develop a vaccine against the 2019 novel coronavirus, the U.S. Department of Health and Human Services' Office of the Assistant Secretary for Preparedness and Response has engaged Sanofi Pasteur, the vaccines global business unit of Sanofi. The Biomedical Advanced Research and Development Authority (BARDA), a component of ASPR, will provide expertise and reallocated funds to support the vaccine's development. Sanofi will use its egg-free, recombinant DNA platform to produce a recombinant 2019 novel coronavirus vaccine candidate.

The technology produces an exact genetic match to proteins of the virus. The protein's DNA will be combined with DNA from a virus harmless to humans, and used to rapidly produce large quantities of antigen which stimulate the immune system to protect against the virus. The antigens will be separated and collected from these cells and purified to create working stocks of vaccine for advanced development.

"Flexibility and scalability are cornerstones of rapid response to an emerging infectious disease," said BARDA Director Rick A. Bright, Ph.D. "Using this proven technology, we can pivot immediately to address this new global health threat. Our goal is a licensed vaccine to provide long-term health security against this latest virus and prevent future coronavirus outbreaks."

BARDA has worked with Sanofi since 2004 and in 2009 began collaborating with Protein Sciences of Meridian, Connecticut, now owned by Sanofi, to develop a recombinant technology with the flexibility to make millions of doses of vaccine quickly in an influenza pandemic. In 2016, BARDA added this vaccine to the U.S. National Pre-pandemic Influenza Vaccine Stockpile. When Sanofi purchased the company and its technology in 2017, BARDA continued working with Sanofi on pandemic vaccine development, and in December 2019 the partners began focusing on increasing [manufacturing capacity](#) for recombinant influenza vaccine in the United States, in accordance with a [presidential executive order](#) to enhance national security and the public health by modernizing influenza vaccines and technologies.

This expanded collaboration with Sanofi is BARDA's second program to focus on developing a novel coronavirus vaccine candidate in the past few weeks. There is currently no approved vaccine, treatment, or diagnostic for novel coronavirus infections; however, the U.S. Food and Drug Administration has issued an emergency use authorization (EUA) to enable emergency use of a diagnostic test developed by the Centers for Disease Control and Prevention.

BARDA also is working with counterparts across the government, including within HHS and with the Department of Defense. The team is reviewing potential vaccines, treatments and diagnostics from across the public and private sectors, particularly products in

development for Middle East Respiratory Syndrome (MERS) or Severe Acute Respiratory Syndrome (SARS), to identify promising candidates for development and licensure to detect, protect against or treat novel coronavirus infections.

To obtain information about any potential products in development in the private sector that could be used in responding to the novel coronavirus outbreak, the U.S. government launched a single point-of-entry [website](#) for innovators and product developers to submit brief descriptions of their diagnostics, therapeutics, vaccines, and other products or technologies relevant to this new virus.


Federal agencies are particularly interested in identifying products and technologies that have progressed into or beyond non-clinical studies, have established large-scale commercial Good Manufacturing Practices (cGMP) manufacturing capability, and/or have utilized a platform already approved by the U.S. Food and Drug Administration (FDA). BARDA also opened an easy broad agency announcement, an [EZ-BAA](#), specific to diagnostics that utilize platforms already cleared by the FDA, with a viable plan to meet requirements for the FDA to consider Emergency Use Authorization (EUA) within 12 weeks of an award.

#### **About HHS, ASPR, and BARDA**

HHS works to enhance and protect the health and well-being of all Americans, providing for effective health and human services and fostering advances in medicine, public health, and social services. The mission of ASPR is to save lives and protect Americans from 21st century health security threats. Within ASPR, BARDA invests in innovation, advanced research and development, acquisition, and manufacturing of medical countermeasures – vaccines, drugs, therapeutics, diagnostic tools, and non-pharmaceutical products needed to combat health security threats. To date, 54 BARDA-supported products have achieved regulatory approval, licensure or clearance. BARDA DRIVe brings together the best ideas from the medical and scientific communities, together with government and venture capital investment, to drive innovation that will strengthen our nation’s health security. To learn more about preparing for and responding to public health emergencies, from new infectious diseases to natural disasters and bioterrorism, by visiting the HHS public health emergency website, [www.phe.gov](http://www.phe.gov). For more information on partnering with BARDA on developing medical countermeasures, visit [www.medicalcountermeasures.gov](http://www.medicalcountermeasures.gov), and for more on DRIVe, visit [drive.hhs.gov](http://drive.hhs.gov).

###

Note: All HHS press releases, fact sheets and other news materials are available at <https://www.hhs.gov/news>.

Like [HHS on Facebook](#) , follow HHS on Twitter [@HHSgov](#) , and sign up for [HHS Email Updates](#).

Last revised: February 18, 2020

**Disclaimer: Any third-party material in this email has been shared for internal use under fair use provisions of U.S. copyright law, without further verification of its accuracy/veracity. It does not necessarily represent my views nor those of NIAID, NIH, HHS, or the U.S. government.**



**From:** Fauci, Anthony (NIH/NIAID) [E]  
**Sent:** Sat, 22 Feb 2020 19:39:17 +0000  
**To:** Kevin Thurm  
**Subject:** RE: Thanks

Kevin:

Many thanks for your kind note. Much appreciated. I hope that all is well with you.

Best regards,

Tony

**Anthony S. Fauci, MD**  
**Director**  
**National Institute of Allergy and Infectious Diseases**  
**Building 31, Room 7A-03**  
**31 Center Drive, MSC 2520**  
**National Institutes of Health**  
**Bethesda, MD 20892-2520**  
**Phone:** (b) (6)  
**FAX:** (301) 496-4409  
**E-mail:** (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

---

**From:** Kevin Thurm (b) (6) >  
**Sent:** Saturday, February 22, 2020 12:45 PM  
**To:** Fauci, Anthony (NIH/NIAID) [E] (b) (6) >; Fauci, Anthony (NIH/NIAID) [E] (b) (6) >  
**Subject:** Thanks

Tony

Good afternoon.

Just wanted to write and say how much I deeply appreciate your on-going public service; you've made extraordinary contributions over the course of your career and, as I've watched you on TV in the context of the current public health threat of the coronavirus, I know you're continuing to do so...

No need to respond; you have a lot going on.

From one citizen and a former colleague, extending my thanks and deep appreciation.

Best wishes.



Kevin Thurm

**From:** Fauci, Anthony (NIH/NIAID) [E]  
**Sent:** Sat, 22 Feb 2020 19:36:40 +0000  
**To:** Folkers, Greg (NIH/NIAID) [E]  
**Subject:** RE: For review: ASM presentation for 26Feb2020  
**Attachments:** ASM Public and Scientific Affairs Committee Meeting 2nd FINAL for 26Feb2020.pptx

I mistakenly put it into my Documents. Here it is, and I will put it into the OD now

**Anthony S. Fauci, MD**  
Director  
National Institute of Allergy and Infectious Diseases  
Building 31, Room 7A-03  
31 Center Drive, MSC 2520  
National Institutes of Health  
Bethesda, MD 20892-2520  
Phone: (b) (6)  
FAX: (301) 496-4409  
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

---

**From:** Folkers, Greg (NIH/NIAID) [E] (b) (6) >  
**Sent:** Saturday, February 22, 2020 2:25 PM  
**To:** Fauci, Anthony (NIH/NIAID) [E] (b) (6)  
**Subject:** RE: For review: ASM presentation for 26Feb2020

I don't see it in OD

---

**From:** Fauci, Anthony (NIH/NIAID) [E] (b) (6) >  
**Sent:** Saturday, February 22, 2020 1:49 PM  
**To:** Schneider, Johanna (NIH/NIAID) [E] <(b) (6)>  
**Cc:** Folkers, Greg (NIH/NIAID) [E] <(b) (6)>; Conrad, Patricia (NIH/NIAID) [E] (b) (6) >  
**Subject:** RE: For review: ASM presentation for 26Feb2020

This is now "2<sup>nd</sup> FINAL" in the OD folder. You just need to remove the instruction slides and do the required updates on several of the slides and then it is ready to go. Thanks.

Anthony S. Fauci, MD  
Director  
National Institute of Allergy and Infectious Diseases  
Building 31, Room 7A-03  
31 Center Drive, MSC 2520  
National Institutes of Health  
Bethesda, MD 20892-2520  
Phone: (b) (6)  
FAX: (301) 496-4409  
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

---

**From:** Schneider, Johanna (NIH/NIAID) [E] (b) (6)  
**Sent:** Friday, February 21, 2020 4:05 PM  
**To:** Fauci, Anthony (NIH/NIAID) [E] (b) (6) >  
**Cc:** Folkers, Greg (NIH/NIAID) [E] (b) (6) >; Conrad, Patricia (NIH/NIAID) [E] (b) (6)  
**Subject:** For review: ASM presentation for 26Feb2020

Dr. Fauci,  
Attached is the presentation to the American Society for Microbiology (ASM) Public and Scientific Affairs Committee on Wednesday Feb 26th.

The topics they have expressed interest in are:

- NIAID Budget Request FY2021
- Novel Coronavirus
- Progress on a Universal Flu Vaccine

The talk is 30 minutes plus 15-20 for discussion.

I've scheduled 30 minutes Monday morning at 10AM to review the slides with you as well.

The presentation has been uploaded to the shared drive. As indicated we will update the necessary slides on Monday afternoon before sending them to ASM on Tuesday.

Thanks,  
Johanna



**From:** Fauci, Anthony (NIH/NIAID) [E]  
**Sent:** Sat, 22 Feb 2020 19:33:57 +0000  
**To:** Cassetti, Cristina (NIH/NIAID) [E]  
**Subject:** RE: Question

Thanks.

**Anthony S. Fauci, MD**  
Director  
National Institute of Allergy and Infectious Diseases  
Building 31, Room 7A-03  
31 Center Drive, MSC 2520  
National Institutes of Health  
Bethesda, MD 20892-2520  
Phone: (b) (6)  
FAX: (301) 496-4409  
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

---

**From:** Cassetti, Cristina (NIH/NIAID) [E] (b) (6)>  
**Sent:** Saturday, February 22, 2020 2:22 PM  
**To:** Fauci, Anthony (NIH/NIAID) [E] (b) (6)  
**Cc:** Erbeling, Emily (NIH/NIAID) [E] (b) (6)>  
**Subject:** Re: Question

Hi Dr. Fauci,

This effort is completely driven by BARDA. DMID is not involved.

Cristina

On Feb 22, 2020, at 2:18 PM, Fauci, Anthony (NIH/NIAID) [E] <(b) (6)> wrote:

Cristina:

What is the relationship that we (DMID/NIAID) has with Sanofi in the development of a coronavirus vaccine? Are we funding them? Do we

have any agreement with them to develop a coronavirus vaccine, or is it BARDA who is dealing with them?

Thanks,

Tony

**Anthony S. Fauci, MD**  
Director  
National Institute of Allergy and Infectious Diseases  
Building 31, Room 7A-03  
31 Center Drive, MSC 2520  
National Institutes of Health  
Bethesda, MD 20892-2520  
Phone: (b) (6)  
FAX: (301) 496-4409  
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

**From:** Fauci, Anthony (NIH/NIAID) [E]  
**Sent:** Sat, 22 Feb 2020 18:32:37 +0000  
**To:** Eisinger, Robert (NIH/NIAID) [E]  
**Cc:** Conrad, Patricia (NIH/NIAID) [E]  
**Subject:** Nabel NAS nomination  
**Attachments:** (b) (6) 2020 NAS Nomination - Section 44 - 02-22-2020.docx

Bob:

Here is (b) (6) NAS nomination. Let us touch bases on Monday to get it uploaded to the website.

Thanks,  
Tony

**Anthony S. Fauci, MD**  
**Director**  
**National Institute of Allergy and Infectious Diseases**  
**Building 31, Room 7A-03**  
**31 Center Drive, MSC 2520**  
**National Institutes of Health**  
**Bethesda, MD 20892-2520**  
**Phone:** (b) (6)  
**FAX: (301) 496-4409**  
**E-mail:** (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.



**From:** Fauci, Anthony (NIH/NIAID) [E]  
**Sent:** Sat, 22 Feb 2020 14:08:16 +0000  
**To:** Marlene Colucci  
**Cc:** David Rubenstein;Ginni Rometty;Donahoe, John  
**Subject:** RE: Business Council - Dr. Anthony Fauci "fireside chat" with David Rubenstein - Thank you!

Marlene: Thanks for the note. It was my pleasure, and I never miss an opportunity to interact with David. He is an incomparable interviewer.

Best,  
Tony

---

**From:** Marlene Colucci <mcolucci@businesscouncil.com>  
**Sent:** Friday, February 21, 2020 2:40 PM  
**To:** Fauci, Anthony (NIH/NIAID) [E] (b) (6)>  
**Cc:** David Rubenstein (b) (6); Ginni Rometty (b) (6); Donahoe, John (b) (6)>  
**Subject:** Business Council - Dr. Anthony Fauci "fireside chat" with David Rubenstein - Thank you!

Dr. Fauci,

We wanted to send a quick note to thank you for joining us today. Your discussion with David was so interesting and well received.

The coronavirus alone was on the minds of so many CEOs as it impacts their supply chain.

David, it goes without saying that you are the best interviewer! You make everything substantive and entertaining.

Wishing everyone an enjoyable weekend!

Warmest regards,

Marlene

**Marlene Colucci**

EXECUTIVE  
DIRECTOR



T: 202-298-7650  
C: [REDACTED] (b) (6)  
F: 202-785-0296

**From:** Fauci, Anthony (NIH/NIAID) [E]  
**Sent:** Sat, 22 Feb 2020 14:06:21 +0000  
**To:** Cassetti, Cristina (NIH/NIAID) [E]  
**Subject:** FW: CoVid-19 in Infants

Please handle.

-----Original Message-----

**From:** JF K [REDACTED] (b) (6)>  
**Sent:** Friday, February 21, 2020 2:44 PM  
**To:** Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6)  
**Subject:** CoVid-19 In Infants

Dr. Fauci,

Infants and children infected with CoVid-19 seem to be an anomaly. Could it be as simple as childhood vaccinations? Are Chinese children vaccinated with anti malarial drugs such as Chloroquine phosphate, which is proving effective in older patients for CoVid-19?

If infants and children are not getting severe infections, why?

Jonathan F. King



**From:** Fauci, Anthony (NIH/NIAID) [E]  
**Sent:** Sat, 22 Feb 2020 14:00:30 +0000  
**To:** Marston, Hilary (NIH/NIAID) [E]  
**Cc:** Conrad, Patricia (NIH/NIAID) [E]; Greg Folkers (GFOLKERS@niaid.nih.gov)  
**Subject:** FW: Session Planning for COVID-19 at CROI; Tuesday March 10, at 12:10 PM Eastern Daylight Time

fyi

---

**From:** Kevin Bowen <kbowen@iasusa.org>  
**Sent:** Friday, February 21, 2020 6:31 PM  
**To:** Donna Jacobsen <djacobsen@iasusa.org>; Zunyou Wu (b) (6); Brooks, John T. (CDC/DDID/NCHHSTP/DHPSE) (b) (6); Baric, Ralph (b) (6) Fauci, Anthony (NIH/NIAID) [E] (b) (6)>  
**Cc:** Sharon Hillier PhD (b) (6); El-Sadr, Wafaa M. (b) (6); Schooley, Robert (b) (6); Schooley, Chip (b) (6); Eron, Joseph J Jr (b) (6); Genesis Regalado (b) (6); Baric, Toni C (b) (6); Conrad, Patricia (NIH/NIAID) [E] (b) (6)>  
**Subject:** RE: Session Planning for COVID-19 at CROI; Tuesday March 10, at 12:10 PM Eastern Daylight Time

Dear CROI Speakers and Moderators:

We would like to schedule a planning call for next week to COVID-19 session at the 2020 Conference on Retroviruses and Opportunistic Infections (CROI). Please submit your availability using the poll at <http://whenisgood.net/ksy42az>. The poll should automatically adjust to your local time zone, but you can adjust the setting using the "Select your location" dropdown if needed.

We will confirm the call as soon as possible.

Regards,

Kevin Bowen  
Program Director  
CROI Scientific Program and IAS-USA Production

---

**From:** Donna Jacobsen  
**Sent:** Friday, February 21, 2020 1:37 PM  
**To:** Zunyou Wu (b) (6); John T. Brooks MD (b) (6); Baric, Ralph S (b) (6); Fauci, Anthony (NIH/NIAID) [E] (b) (6)>  
**Cc:** Sharon Hillier PhD (b) (6); El-Sadr, Wafaa M. (b) (6); Kevin Bowen <kbowen@iasusa.org>; Schooley, Robert (b) (6) 'Robert T. Schooley, MD (b) (6); Eron, Joseph J Jr (b) (6); Kevin Bowen <kbowen@iasusa.org>; Genesis Regalado <gregalado@iasusa.org>; Baric, Toni C

(b) (6) >; Conrad, Patricia (NIH/NIAID) [E]

(b) (6) >

**Subject:** Session Planning for COVID-19 at CROI; Tuesday March 10, at 12:10 PM Eastern Daylight Time  
**Importance:** High

Dear Drs Wu, Brooks, Baric, and Fauci:

It is more than incredibly impressive at how all of you, in just the past few days, have rearranged your schedules and agreed to participate in this special session in only about 2 weeks. We are all very grateful, and know this will be tremendously impactful for the CROI audience.

Below is the final list of presentations, although the order and titles may well change. We are hoping to have a conference call with the session liaisons and speakers next week if possible, to go over each of the talks to address the overall plan and discuss any overlap. Shortly we will send out a poll for availability for early morning in China, early-mid afternoon in the US West Coast, and late afternoon-evening in the US East Coast. If you can respond to the poll by Monday we would greatly appreciate it; things are moving quickly.

Many thanks again,

All of us at CROI!

**SPECIAL LUNCHTIME SESSION ON COVID 19**

Tue. 3/10: 12:10 PM - 1:20 PM EASTERN DAYLIGHT TIME  
Auditorium

Preliminary Session Agenda (Order and talk titles to be confirmed)

1. FOCUS ON THE EPIDEMIOLOGY OF COVID-19 AND EFFORTS IN CHINA
  - a. Zhenyou Wu, Chinese Center for Disease Control, China  
15-minute live video (Skype or Zoom) update from China
2. FOCUS ON THE GLOBAL EPIDEMIOLOGY OF COVID-19 AND EFFORTS TO CONTROL THE OUTBREAK
  - a. John Brooks, US Centers for Disease Control, USA  
15-minute update
3. FOCUS ON THE VIROLOGY OF CORONAVIRUSES OVERALL, MOLECULAR ASPECTS OF TRANSMISSION TO HUMANS, PATHOGENESIS IN MICE MODELS AND PARALLELS IN HUMANS, ETC
  - a. Ralph Baric, University of North Carolina, USA  
25-minute lecture
4. FOCUS ON NIAID/NIH EFFORTS TO STUDY NOVEL CORONAVIRUSES AND DEVELOP DIAGNOSTICS, THERAPEUTICS, AND VACCINES
  - a. Anthony Fauci, National Institute of Allergy and Infectious Diseases, National Institutes of Health, USA  
15-minute recorded update

**From:** Fauci, Anthony (NIH/NIAID) [E]  
**Sent:** Sat, 22 Feb 2020 12:13:45 +0000  
**To:** Conrad, Patricia (NIH/NIAID) [E]  
**Subject:** FW: Triple E letter

Let us discuss. Likely no.

-----Original Message-----

**From:** Bridbord, Ken (NIH/FIC) [V] (b) (6)>  
**Sent:** Friday, February 21, 2020 3:56 PM  
**To:** Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>  
**Cc:** Marietta Ethier (b) (6); Emily Lane <ELane@ (b) (6)>; Fauci, Anthony (NIH/NIAID) [E] (b) (6)  
**Subject:** Re: Triple E letter

Tony, my condominium community has established a program in which prominent members of the Washington area are invited to make presentations on subjects of great public interest. Shown in the email below is a description of this program. In this regard I have been asked to contact you to see, recognizing your incredibly busy schedule, if you would be interested and able to provide an update on the Coronavirus situation to our residents. Most likely you (b) (6) If you have a potential interest in sharing your great expertise on this subject with our residents could you please have your staff contact Emily Lane who is copied on this email to explore possible dates and times that would work for you. Thank you so much for your consideration of this request. Ken

On 2/21/20, 3:36 PM, "Emily Lane" <ELane@ (b) (6)> wrote:

Dear Ken,

The (b) (6) Committee greatly appreciates your willingness to approach Dr. Anthony Fauci on our behalf, asking him to address the residents of the (b) (6) on the Coronavirus. It would perhaps be helpful to Dr. Fauci, to explain who we are and what we do. (b) (6), (b) (6)

The (b) (6) Committee was formed recently to create and organize events to educate, enlighten and entertain members of the Somerset community. A few weeks ago (b) (6) spoke to a sold out crowd on impeachment. We've featured authors on a variety of topics; invited doctors with specialties of interest to our community organized trips to the Kennedy Center and theaters for attendance at ballets and plays and sponsored visits, led by experts, to various museums and the Library of Congress to view special exhibitions. An example of the latter is a tour of the Folger Library (b) (6). A presentation by Dr. Fauci on the coronavirus would be of great interest to our constituency who keep informed by reading both national and international journals. We are flexible on the date for such an appearance needing only a few days' notice to inform our residents.

I need not tell you that it would our great honor to welcome Dr. Fauci to the (b) (6).



Sincerely

[Redacted signature block]

(b) (6)

**From:** Fauci, Anthony (NIH/NIAID) [E]  
**Sent:** Sat, 22 Feb 2020 12:08:24 +0000  
**To:** Conrad, Patricia (NIH/NIAID) [E];Folkers, Greg (NIH/NIAID) [E]  
**Cc:** Marston, Hilary (NIH/NIAID) [E];Barasch, Kimberly (NIH/NIAID) [C]  
**Subject:** RE: Session Planning for COVID-19 at CROI, Tuesday March 10, at 12:10 PM Eastern Daylight Time

I totally agree. I do not want to be on a "session planning" call. Please have Hilary do this as suggested by Patty since she is preparing the talk. Thanks.

---

**From:** Conrad, Patricia (NIH/NIAID) [E] (b) (6)>  
**Sent:** Friday, February 21, 2020 4:44 PM  
**To:** Folkers, Greg (NIH/NIAID) [E] (b) (6)>; Fauci, Anthony (NIH/NIAID) [E] (b) (6)  
**Subject:** FW: Session Planning for COVID-19 at CROI; Tuesday March 10, at 12:10 PM Eastern Daylight Time  
**Importance:** High

Since this is a taping for his remarks – can hilary do this call since she is doing the slides? hate to waste ASF time on this with all our other moving parts....just a thought.

Patricia L. Conrad  
Public Health Analyst and  
Special Assistant to the Director  
National Institute of Allergy and Infectious Diseases  
The National Institutes of Health  
31 Center Drive, MSC 2520 - Room 7A03  
Bethesda, Maryland 20892  
(b) (6)  
301-496-4409 fax

Disclaimer:

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statement made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

---

**From:** Donna Jacobsen <[djacobsen@iasusa.org](mailto:djacobsen@iasusa.org)>  
**Sent:** Friday, February 21, 2020 4:37 PM  
**To:** Zunyou Wu (b) (6)>; Brooks, John T. (CDC/DDID/NCHHSTP/DHPSE) (b) (6)>; Baric, Ralph (b) (6)>; Fauci, Anthony (NIH/NIAID) [E] (b) (6)>  
**Cc:** Sharon Hillier PhD (b) (6);

(b) (6) El-Sadr, Wafaa M. (b) (6); Kevin Bowen  
(b) (6); Schooley, Robert (b) (6); Schooley, Chip  
>; Eron, Joseph J Jr >; Kevin Bowen  
>; Genesis Regalado (b) (6); Baric, Toni C  
(b) (6), Conrad, Patricia (NIH/NIAID) [E] (b) (6)

**Subject:** Session Planning for COVID-19 at CROI; Tuesday March 10, at 12:10 PM Eastern Daylight Time  
**Importance:** High

Dear Drs Wu, Brooks, Baric, and Fauci:

It is more than incredibly impressive at how all of you, in just the past few days, have rearranged your schedules and agreed to participate in this special session in only about 2 weeks. We are all very grateful, and know this will be tremendously impactful for the CROI audience.

Below is the final list of presentations, although the order and titles may well change. We are hoping to have a conference call with the session liaisons and speakers next week if possible, to go over each of the talks to address the overall plan and discuss any overlap. Shortly we will send out a poll for availability for early morning in China, early-mid afternoon in the US West Coast, and late afternoon-evening in the US East Coast. If you can respond to the poll by Monday we would greatly appreciate it; things are moving quickly.

Many thanks again,

All of us at CROI!

**SPECIAL LUNCHTIME SESSION ON COVID 19**

Tue. 3/10: 12:10 PM - 1:20 PM EASTERN DAYLIGHT TIME  
Auditorium

Preliminary Session Agenda (Order and talk titles to be confirmed)

1. FOCUS ON THE EPIDEMIOLOGY OF COVID-19 AND EFFORTS IN CHINA
  - a. Zunyou Wu, Chinese Center for Disease Control, China  
15-minute live video (Skype or Zoom) update from China
2. FOCUS ON THE GLOBAL EPIDEMIOLOGY OF COVID-19 AND EFFORTS TO CONTROL THE OUTBREAK
  - a. John Brooks, US Centers for Disease Control, USA  
15-minute update
3. FOCUS ON THE VIROLOGY OF CORONAVIRUSES OVERALL, MOLECULAR ASPECTS OF TRANSMISSION TO HUMANS, PATHOGENESIS IN MICE MODELS AND PARALLELS IN HUMANS, ETC
  - a. Ralph Baric, University of North Carolina, USA  
25-minute lecture
4. FOCUS ON NIAID/NIH EFFORTS TO STUDY NOVEL CORONAVIRUSES AND DEVELOP DIAGNOSTICS, THERAPEUTICS, AND VACCINES
  - a. Anthony Fauci, National Institute of Allergy and Infectious Diseases, National Institutes of Health, USA  
15-minute recorded update



**From:** Fauci, Anthony (NIH/NIAID) [E]  
**Sent:** Sat, 22 Feb 2020 12:06:10 +0000  
**To:** Casetti, Cristina (NIH/NIAID) [E]  
**Subject:** FW: DEAR TONY: CORONAVIRUS

Please handle.

**From:** Dr. Michael Jacobs (b) (6) >  
**Sent:** Friday, February 21, 2020 6:14 PM  
**To:** Fauci, Anthony (NIH/NIAID) [E] (b) (6) >  
**Cc:** Alexander Tarakhovsky (b) (6); Lockshin, Michael MD (b) (6); Dr. Michael Jacobs (b) (6) >  
**Subject:** DEAR TONY: CORONAVIRUS

dear tony:

i am a cornell medical school cumc (b) (6) graduate. i am associate professor of dermatology at weill-cornell in private practice. (b) (6)  
(b) (6) alexander tarakhovsky is (b) (6) and a professor at rockefeller university. he is a virologist.

we have been following the corona virus pandemic closely, and a few days ago became alarmed at the news that the chinese government is sterilizing their paper money from hubei province.

we think that there is a possibility that the virus was released from a lab in wuhan, the biotech area of china. we also think that the virus might be complexed with another organism, such as a yeast or fungus, to make it more sticky.

we would like to discuss this with you further. we feel that immediate action must be taken by united states scientists to try to neutralize this threat.

please contact alexander and me at your earliest convenience at above emails or my mobile (b) (6) or office (b) (6) michael lockshin gave me your email.

with kind regards

michael jacobs

**From:** Fauci, Anthony (NIH/NIAID) [E]  
**Sent:** Sat, 22 Feb 2020 11:49:36 +0000  
**To:** Cassetti, Cristina (NIH/NIAID) [E]  
**Subject:** FW: coronavirus  
**Attachments:** Cai & Garen 1995.pdf, Cai & Garen 1996 .pdf, Cai & Garen 1997.pdf

Please handle. Thanks.

---

**From:** Garen, Alan [REDACTED] (b) (6) >  
**Sent:** Friday, February 21, 2020 7:46 PM  
**To:** Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6) >  
**Cc:** Garen, Alan [REDACTED] (b) (6) >  
**Subject:** coronavirus

Dear D. Fauci,

I want to suggest that NIAID arrange to collect serum samples from Coronavirus patients who have survived a major infection and probably have generated antiviral antibodies. My laboratory showed in the attached papers that such antibodies could be cloned from sera using a powerful technology called Phage Display. The project could be initiated in this country with as few as 2 patients.

Sincerely, Alan Garen, Yale University

**From:** Fauci, Anthony (NIH/NIAID) [E]  
**Sent:** Sat, 22 Feb 2020 11:39:57 +0000  
**To:** Antoniak, Cynthia (NBCUniversal, MSNBC)  
**Cc:** Goldner, Shannah (NBCUniversal); Conrad, Patricia (NIH/NIAID) [E]  
**Subject:** RE: MSNBC Reconfirming

No problem. See you then.

---

**From:** Antoniak, Cynthia (NBCUniversal, MSNBC) <Cynthia.Antoniak@MSNBC.COM>  
**Sent:** Saturday, February 22, 2020 6:39 AM  
**To:** Fauci, Anthony (NIH/NIAID) [E] (b) (6)>  
**Cc:** Goldner, Shannah (NBCUniversal) <shannah.goldner@nbcuni.com>; Conrad, Patricia (NIH/NIAID) [E] (b) (6)  
**Subject:** RE: MSNBC Reconfirming

If you could get there by 7:30am...that would be great!

---

**From:** Fauci, Anthony (NIH/NIAID) [E] (b) (6)>  
**Sent:** Saturday, February 22, 2020 6:38 AM  
**To:** Antoniak, Cynthia (NBCUniversal, MSNBC) <Cynthia.Antoniak@MSNBC.COM>  
**Cc:** Goldner, Shannah (NBCUniversal) <shannah.goldner@nbcuni.com>; Conrad, Patricia (NIH/NIAID) [E] (b) (6)>  
**Subject:** [EXTERNAL] RE: MSNBC Reconfirming

I have received this e-mail and confirm 7:45 AM hit. What time do you want me at the studio?

---

**From:** Antoniak, Cynthia (NBCUniversal, MSNBC) <Cynthia.Antoniak@MSNBC.COM>  
**Sent:** Saturday, February 22, 2020 5:49 AM  
**To:** Fauci, Anthony (NIH/NIAID) [E] (b) (6)>  
**Cc:** Goldner, Shannah (NBCUniversal) <shannah.goldner@nbcuni.com>; Conrad, Patricia (NIH/NIAID) [E] (b) (6)  
**Subject:** MSNBC Reconfirming

Good Morning Dr. Fauci,

I am just reconfirming you for your segment on MSNBC this morning with Kendis Gibson and Cori Coffin.

You are hitting at 7:45am from the NBC News Bureau at 4001 Nebraska Avenue.

Topics:

-Coronavirus-infected Americans flown home against CDC advice

[https://www.washingtonpost.com/health/coronavirus-diamond-princess-cruise-americans/2020/02/20/b6f54cae-5279-11ea-b119-4faabac6674f\\_story.html](https://www.washingtonpost.com/health/coronavirus-diamond-princess-cruise-americans/2020/02/20/b6f54cae-5279-11ea-b119-4faabac6674f_story.html)

-Decision to quarantine cruise ship—was that a misstep?

-Long term effects of decision to bring U.S. passengers back



Please reply that you got this.  
Thank you!  
Cyndi

---

**From:** Goldner, Shannah (NBCUniversal) <[shannah.goldner@nbcuni.com](mailto:shannah.goldner@nbcuni.com)>  
**Sent:** Friday, February 21, 2020 3:09 PM  
**To:** Conrad, Patricia (NIH/NIAID) [E] (b) (6)>  
**Cc:** Antoniak, Cynthia (NBCUniversal, MSNBC) <[Cynthia.Antoniak@MSNBC.COM](mailto:Cynthia.Antoniak@MSNBC.COM)>; Fauci, Anthony (NIH/NIAID) [E] (b) (6)  
**Subject:** RE: contact at the studio tomorrow/MSNBC intv

We absolutely will do. Thank you so much and thank you for your patience. We will be in touch first thing in the morning.

---

**From:** Conrad, Patricia (NIH/NIAID) [E] (b) (6)  
**Sent:** Friday, February 21, 2020 3:04 PM  
**To:** Goldner, Shannah (NBCUniversal) <[shannah.goldner@nbcuni.com](mailto:shannah.goldner@nbcuni.com)>  
**Cc:** Antoniak, Cynthia (NBCUniversal, MSNBC) <[Cynthia.Antoniak@MSNBC.COM](mailto:Cynthia.Antoniak@MSNBC.COM)>; Fauci, Anthony (NIH/NIAID) [E] (b) (6)  
**Subject:** [EXTERNAL] RE: contact at the studio tomorrow/MSNBC intv

Ok – I am adding Dr Fauci to this email - please confirm to both of us in the morning. Thank you

Patricia L. Conrad  
Public Health Analyst and  
Special Assistant to the Director  
National Institute of Allergy and Infectious Diseases  
The National Institutes of Health  
31 Center Drive, MSC 2520 - Room 7A03  
Bethesda, Maryland 20892  
(b) (6)  
301-496-4409 fax

Disclaimer:

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statement made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

---

**From:** Goldner, Shannah (NBCUniversal) <[shannah.goldner@nbcuni.com](mailto:shannah.goldner@nbcuni.com)>  
**Sent:** Friday, February 21, 2020 2:55 PM  
**To:** Conrad, Patricia (NIH/NIAID) [E] (b) (6)  
**Cc:** Antoniak, Cynthia (NBCUniversal, MSNBC) <[Cynthia.Antoniak@MSNBC.COM](mailto:Cynthia.Antoniak@MSNBC.COM)>  
**Subject:** RE: contact at the studio tomorrow/MSNBC intv

We won't have an exact hit time until the morning BUT as of now, it's 7:30am. It might be 7:35am but that is the hit time.

Cyndi will send it to you by 5am tomorrow.

---

**From:** Conrad, Patricia (NIH/NIAID) [E] (b) (6)>  
**Sent:** Friday, February 21, 2020 2:48 PM  
**To:** Goldner, Shannah (NBCUniversal) <[shannah.goldner@nbcuni.com](mailto:shannah.goldner@nbcuni.com)>  
**Cc:** Antoniak, Cynthia (NBCUniversal, MSNBC) <[Cynthia.Antoniak@MSNBC.COM](mailto:Cynthia.Antoniak@MSNBC.COM)>  
**Subject:** [EXTERNAL] RE: contact at the studio tomorrow/MSNBC intv

Will you or Cyndi send exact hit time tonight? What is the approx. time we will get that?

Patricia L. Conrad  
Public Health Analyst and  
Special Assistant to the Director  
National Institute of Allergy and Infectious Diseases  
The National Institutes of Health  
31 Center Drive, MSC 2520 - Room 7A03  
Bethesda, Maryland 20892

(b) (6)  
301-496-4409 fax

Disclaimer:

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases (NIAID) shall not accept

liability for any statement made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

---

**From:** Goldner, Shannah (NBCUniversal) <[shannah.goldner@nbcuni.com](mailto:shannah.goldner@nbcuni.com)>  
**Sent:** Friday, February 21, 2020 10:42 AM  
**To:** Conrad, Patricia (NIH/NIAID) [E] (b) (6)  
**Cc:** Robinson, Whitney (NIH/NIAID) [C] (b) (6); Deatrick, Elizabeth (NIH/NIAID) [C] (b) (6); Lavelle, Judith (NIH/NIAID) [E] (b) (6)>  
**Subject:** RE: contact at the studio tomorrow/MSNBC intv

Thank you so much

---

**From:** Conrad, Patricia (NIH/NIAID) [E] (b) (6)  
**Sent:** Friday, February 21, 2020 10:35 AM  
**To:** Goldner, Shannah (NBCUniversal) <[shannah.goldner@nbcuni.com](mailto:shannah.goldner@nbcuni.com)>  
**Cc:** Robinson, Whitney (NIH/NIAID) [C] (b) (6); Deatrick, Elizabeth (NIH/NIAID) [C] (b) (6); Lavelle, Judith (NIH/NIAID) [E] (b) (6)>  
**Subject:** [EXTERNAL] RE: contact at the studio tomorrow/MSNBC intv



Great – thanks.

Please just let us know the exact time and we will have him arrive 20 mins prior.

His cell is (b) (6) and mine is (b) (6)

Patricia L. Conrad  
Public Health Analyst and  
Special Assistant to the Director  
National Institute of Allergy and Infectious Diseases  
The National Institutes of Health  
31 Center Drive, MSC 2520 - Room 7A03  
Bethesda, Maryland 20892  
(b) (6)  
301-496-4409 fax

Disclaimer:

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statement made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

---

**From:** Goldner, Shannah (NBCUniversal) <[shannah.goldner@nbcuni.com](mailto:shannah.goldner@nbcuni.com)>  
**Sent:** Friday, February 21, 2020 10:29 AM  
**To:** Conrad, Patricia (NIH/NIAID) [E] <(b) (6)>  
**Cc:** Robinson, Whitney (NIH/NIAID) [C] (b) (6); Deatrick, Elizabeth (NIH/NIAID) [C] (b) (6); Lavelle, Judith (NIH/NIAID) [E] (b) (6)  
**Subject:** contact at the studio tomorrow/MSNBC intv  
**Importance:** High

Patricia, hi,

The contact at the studio in the morning is Natalia Abrams. The number at the office is 202-885-4800. Also, Cyndi Antoniak will be in touch with you in the morning and send you an email about the segment and just to touch base. If you need to reach Cyndi before she reaches you, her number is 212-664-1450 and her email is [Cynthia.antoniak@nbcuni.com](mailto:Cynthia.antoniak@nbcuni.com).

Thank you so much for making the interview work out, we appreciate it.

Shannah

---

**From:** Conrad, Patricia (NIH/NIAID) [E] <(b) (6)>  
**Sent:** Friday, February 21, 2020 9:06 AM  
**To:** Goldner, Shannah (NBCUniversal) <[shannah.goldner@nbcuni.com](mailto:shannah.goldner@nbcuni.com)>  
**Cc:** Robinson, Whitney (NIH/NIAID) [C] (b) (6); Deatrick, Elizabeth (NIH/NIAID) [C]



(b) (6); Lavelle, Judith (NIH/NIAID) [E]

(b) (6)>

**Subject:** [EXTERNAL] RE: hi and request for Dr. Fauci this weekend on MSNBC

Hi Shannah

Saturday Morning between 7:30 am ET – 8 am ET is best for Dr Fauci and will need to be from the NBC Studio at 4001 Nebraska Ave NW studio. He has a hard stop no later than 8:15 am. Please send us the onsite contact name and number and firm hit time when you can.

Thanks,  
-patty

Patricia L. Conrad  
Public Health Analyst and  
Special Assistant to the Director  
National Institute of Allergy and Infectious Diseases  
The National Institutes of Health  
31 Center Drive, MSC 2520 - Room 7A03  
Bethesda, Maryland 20892

(b) (6)

301-496-4409 fax

**Disclaimer:**

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statement made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

---

**From:** Goldner, Shannah (NBCUniversal) <[shannah.goldner@nbcuni.com](mailto:shannah.goldner@nbcuni.com)>

**Sent:** Thursday, February 20, 2020 4:17 PM

**To:** Conrad, Patricia (NIH/NIAID) [E] (b) (6)>

**Cc:** Barasch, Kimberly (NIH/NIAID) [C] (b) (6); Deatrick, Elizabeth (NIH/NIAID) [C]

(b) (6)

**Subject:** RE: hi and request for Dr. Fauci this weekend on MSNBC

That's terrific and yes, that studio is best if he can join us. Thank you so much. Shannah

---

**From:** Conrad, Patricia (NIH/NIAID) [E] (b) (6)

**Sent:** Thursday, February 20, 2020 4:16 PM

**To:** Goldner, Shannah (NBCUniversal) <[shannah.goldner@nbcuni.com](mailto:shannah.goldner@nbcuni.com)>

**Cc:** Barasch, Kimberly (NIH/NIAID) [C] (b) (6); Deatrick, Elizabeth (NIH/NIAID) [C]

(b) (6)

**Subject:** [EXTERNAL] RE: hi and request for Dr. Fauci this weekend on MSNBC

I am sure we can make one of these work – will let you know tomorrow.  
We would do from the NBC Nebraska Ave NW Studio.

thx

Patricia L. Conrad  
Public Health Analyst and  
Special Assistant to the Director  
National Institute of Allergy and Infectious Diseases  
The National Institutes of Health  
31 Center Drive, MSC 2520 - Room 7A03  
Bethesda, Maryland 20892  
(b) (6)  
301-496-4409 fax

Disclaimer:

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statement made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

---

**From:** Goldner, Shannah (NBCUniversal) <[shannah.goldner@nbcuni.com](mailto:shannah.goldner@nbcuni.com)>  
**Sent:** Thursday, February 20, 2020 4:12 PM  
**To:** Conrad, Patricia (NIH/NIAID) [E] (b) (6)>  
**Cc:** Barasch, Kimberly (NIH/NIAID) [C] (b) (6); Deatrick, Elizabeth (NIH/NIAID) [C] (b) (6)  
**Subject:** hi and request for Dr. Fauci this weekend on MSNBC  
**Importance:** High

Patricia, hi, I hope all is well with you.

Is Dr. Fauci available this weekend to be on MSNBC to discuss the latest re Corona virus -

[https://www.washingtonpost.com/health/coronavirus-diamond-princess-cruise-americans/2020/02/20/b6f54cae-5279-11ea-b119-4faabac6674f\\_story.html](https://www.washingtonpost.com/health/coronavirus-diamond-princess-cruise-americans/2020/02/20/b6f54cae-5279-11ea-b119-4faabac6674f_story.html)

We'd like him on either on Saturday, in the 7:30am to 8am half hour, with Kendis Gibson/Cori Coffin, or on Sunday in the 12pm or 1pm hour with Alex Witt. Whatever day/hour that is good for him, we'll make work.

Thank you so much for your help in this matter.

All the best,

Shannah

Shannah Goldner  
MSNBC  
W: 212-664-1289  
C: (b) (6)



**From:** Fauci, Anthony (NIH/NIAID) [E]  
**Sent:** Sat, 22 Feb 2020 11:39:06 +0000  
**To:** Conrad, Patricia (NIH/NIAID) [E]  
**Subject:** RE: MSNBC Reconfirming

I just did reconfirm with a copy to you. Did you not get it?

---

**From:** Conrad, Patricia (NIH/NIAID) [E] (b) (6) >  
**Sent:** Saturday, February 22, 2020 6:38 AM  
**To:** Fauci, Anthony (NIH/NIAID) [E] <(b) (6) >  
**Subject:** Fwd: MSNBC Reconfirming

You need to respond to this. It's in your on box

Sent from my iPhone

Begin forwarded message:

**From:** "Antoniak, Cynthia (NBCUniversal, MSNBC)" <[Cynthia.Antoniak@MSNBC.COM](mailto:Cynthia.Antoniak@MSNBC.COM)>  
**Date:** February 22, 2020 at 5:49:00 AM EST  
**To:** "Fauci, Anthony (NIH/NIAID) [E]" (b) (6) >  
**Cc:** "Goldner, Shannah (NBCUniversal)" <[shannah.goldner@nbcuni.com](mailto:shannah.goldner@nbcuni.com)>, "Conrad, Patricia (NIH/NIAID) [E]" (b) (6)  
**Subject:** MSNBC Reconfirming

Good Morning Dr. Fauci,

I am just reconfirming you for your segment on MSNBC this morning with Kendis Gibson and Cori Coffin.

You are hitting at 7:45am from the NBC News Bureau at 4001 Nebraska Avenue.

Topics:

-Coronavirus-infected Americans flown home against CDC advice

[https://www.washingtonpost.com/health/coronavirus-diamond-princess-cruise-americans/2020/02/20/b6f54cae-5279-11ea-b119-4faabac6674f\\_story.html](https://www.washingtonpost.com/health/coronavirus-diamond-princess-cruise-americans/2020/02/20/b6f54cae-5279-11ea-b119-4faabac6674f_story.html)

-Decision to quarantine cruise ship—was that a misstep?

-Long term effects of decision to bring U.S. passengers back

Please reply that you got this.

Thank you!

Cyndi

---

**From:** Goldner, Shannah (NBCUniversal) <[shannah.goldner@nbcuni.com](mailto:shannah.goldner@nbcuni.com)>  
**Sent:** Friday, February 21, 2020 3:09 PM  
**To:** Conrad, Patricia (NIH/NIAID) [E] (b) (6)

**Cc:** Antoniak, Cynthia (NBCUniversal, MSNBC) <[Cynthia.Antoniak@MSNBC.COM](mailto:Cynthia.Antoniak@MSNBC.COM)>; Fauci, Anthony (NIH/NIAID) [E] <[REDACTED] (b) (6)>  
**Subject:** RE: contact at the studio tomorrow/MSNBC intv

We absolutely will do. Thank you so much and thank you for your patience. We will be in touch first thing in the morning.

---

**From:** Conrad, Patricia (NIH/NIAID) [E] <[REDACTED] (b) (6)>  
**Sent:** Friday, February 21, 2020 3:04 PM  
**To:** Goldner, Shannah (NBCUniversal) <[shannah.goldner@nbcuni.com](mailto:shannah.goldner@nbcuni.com)>  
**Cc:** Antoniak, Cynthia (NBCUniversal, MSNBC) <[Cynthia.Antoniak@MSNBC.COM](mailto:Cynthia.Antoniak@MSNBC.COM)>; Fauci, Anthony (NIH/NIAID) [E] <[REDACTED] (b) (6)>  
**Subject:** [EXTERNAL] RE: contact at the studio tomorrow/MSNBC intv

Ok – I am adding Dr Fauci to this email - please confirm to both of us in the morning. Thank you

Patricia L. Conrad  
Public Health Analyst and  
Special Assistant to the Director  
National Institute of Allergy and Infectious Diseases  
The National Institutes of Health  
31 Center Drive, MSC 2520 - Room 7A03  
Bethesda, Maryland 20892  
[REDACTED] (b) (6)  
301-496-4409 fax

Disclaimer:  
The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statement made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

---

**From:** Goldner, Shannah (NBCUniversal) <[shannah.goldner@nbcuni.com](mailto:shannah.goldner@nbcuni.com)>  
**Sent:** Friday, February 21, 2020 2:55 PM  
**To:** Conrad, Patricia (NIH/NIAID) [E] <[REDACTED] (b) (6)>  
**Cc:** Antoniak, Cynthia (NBCUniversal, MSNBC) <[Cynthia.Antoniak@MSNBC.COM](mailto:Cynthia.Antoniak@MSNBC.COM)>  
**Subject:** RE: contact at the studio tomorrow/MSNBC intv

We won't have an exact hit time until the morning BUT as of now, it's 7:30am. It might be 7:35am but that is the hit time.  
Cyndi will send it to you by 5am tomorrow.

---

**From:** Conrad, Patricia (NIH/NIAID) [E] <[REDACTED] (b) (6)>  
**Sent:** Friday, February 21, 2020 2:48 PM

**To:** Goldner, Shannah (NBCUniversal) <[shannah.goldner@nbcuni.com](mailto:shannah.goldner@nbcuni.com)>  
**Cc:** Antoniak, Cynthia (NBCUniversal, MSNBC) <[Cynthia.Antoniak@MSNBC.COM](mailto:Cynthia.Antoniak@MSNBC.COM)>  
**Subject:** [EXTERNAL] RE: contact at the studio tomorrow/MSNBC intv

Will you or Cyndi send exact hit time tonight? What is the approx. time we will get that?

Patricia L. Conrad  
Public Health Analyst and  
Special Assistant to the Director  
National Institute of Allergy and Infectious Diseases  
The National Institutes of Health  
31 Center Drive, MSC 2520 - Room 7A03  
Bethesda, Maryland 20892  
(b) (6)  
301-496-4409 fax

Disclaimer:

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statement made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

---

**From:** Goldner, Shannah (NBCUniversal) <[shannah.goldner@nbcuni.com](mailto:shannah.goldner@nbcuni.com)>  
**Sent:** Friday, February 21, 2020 10:42 AM  
**To:** Conrad, Patricia (NIH/NIAID) [E] (b) (6)>  
**Cc:** Robinson, Whitney (NIH/NIAID) [C] (b) (6); Deatrick, Elizabeth (NIH/NIAID) [C] <(b) (6)>; Lavelle, Judith (NIH/NIAID) [E] (b) (6)  
**Subject:** RE: contact at the studio tomorrow/MSNBC intv

Thank you so much

---

**From:** Conrad, Patricia (NIH/NIAID) [E] (b) (6)  
**Sent:** Friday, February 21, 2020 10:35 AM  
**To:** Goldner, Shannah (NBCUniversal) <[shannah.goldner@nbcuni.com](mailto:shannah.goldner@nbcuni.com)>  
**Cc:** Robinson, Whitney (NIH/NIAID) [C] (b) (6); Deatrick, Elizabeth (NIH/NIAID) [C] (b) (6); Lavelle, Judith (NIH/NIAID) [E] (b) (6)  
**Subject:** [EXTERNAL] RE: contact at the studio tomorrow/MSNBC intv

Great – thanks.



Please just let us know the exact time and we will have him arrive 20 mins prior.

His cell is (b) (6) and mine is (b) (6)

Patricia L. Conrad  
Public Health Analyst and  
Special Assistant to the Director  
National Institute of Allergy and Infectious Diseases  
The National Institutes of Health  
31 Center Drive, MSC 2520 - Room 7A03  
Bethesda, Maryland 20892  
(b) (6)  
301-496-4409 fax

Disclaimer:

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statement made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

---

**From:** Goldner, Shannah (NBCUniversal) <[shannah.goldner@nbcuni.com](mailto:shannah.goldner@nbcuni.com)>  
**Sent:** Friday, February 21, 2020 10:29 AM  
**To:** Conrad, Patricia (NIH/NIAID) [E] (b) (6)>  
**Cc:** Robinson, Whitney (NIH/NIAID) [C] (b) (6)>; Deatrck, Elizabeth (NIH/NIAID) [C] (b) (6); Lavelle, Judith (NIH/NIAID) [E] (b) (6)>  
**Subject:** contact at the studio tomorrow/MSNBC intv  
**Importance:** High

Patricia, hi,  
The contact at the studio in the morning is Natalia Abrams. The number at the office is 202-885-4800.  
Also, Cyndi Antoniak will be in touch with you in the morning and send you an email about the segment and just to touch base. If you need to reach Cyndi before she reaches you, her number is 212-664- 1450 and her email is [Cynthia.antoniak@nbcuni.com](mailto:Cynthia.antoniak@nbcuni.com) .  
Thank you so much for making the interview work out, we appreciate it.  
Shannah

---

**From:** Conrad, Patricia (NIH/NIAID) [E] (b) (6)  
**Sent:** Friday, February 21, 2020 9:06 AM  
**To:** Goldner, Shannah (NBCUniversal) <[shannah.goldner@nbcuni.com](mailto:shannah.goldner@nbcuni.com)>  
**Cc:** Robinson, Whitney (NIH/NIAID) [C] <(b) (6)>; Deatrck, Elizabeth (NIH/NIAID) [C] <(b) (6)>; Lavelle, Judith (NIH/NIAID) [E]

(b) (6)

**Subject:** [EXTERNAL] RE: hi and request for Dr. Fauci this weekend on MSNBC

Hi Shannah

Saturday Morning between 7:30 am ET – 8 am ET is best for Dr Fauci and will need to be from the NBC Studio at 4001 Nebraska Ave NW studio. He has a hard stop no later than 8:15 am. Please send us the onsite contact name and number and firm hit time when you can.

Thanks,  
-patty

Patricia L. Conrad  
Public Health Analyst and  
Special Assistant to the Director  
National Institute of Allergy and Infectious Diseases  
The National Institutes of Health  
31 Center Drive, MSC 2520 - Room 7A03  
Bethesda, Maryland 20892

(b) (6)

301-496-4409 fax

**Disclaimer:**

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statement made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

---

**From:** Goldner, Shannah (NBCUniversal) <[shannah.goldner@nbcuni.com](mailto:shannah.goldner@nbcuni.com)>

**Sent:** Thursday, February 20, 2020 4:17 PM

**To:** Conrad, Patricia (NIH/NIAID) [E] (b) (6)

**Cc:** Barasch, Kimberly (NIH/NIAID) [C] (b) (6); Deatrick, Elizabeth (NIH/NIAID) [C] (b) (6)

**Subject:** RE: hi and request for Dr. Fauci this weekend on MSNBC

That's terrific and yes, that studio is best if he can join us. Thank you so much. Shannah

---

**From:** Conrad, Patricia (NIH/NIAID) [E] (b) (6)

**Sent:** Thursday, February 20, 2020 4:16 PM

**To:** Goldner, Shannah (NBCUniversal) <[shannah.goldner@nbcuni.com](mailto:shannah.goldner@nbcuni.com)>

**Cc:** Barasch, Kimberly (NIH/NIAID) [C] (b) (6); Deatrick, Elizabeth

(NIH/NIAID) [C] <[REDACTED] (b) (6)>

**Subject:** [EXTERNAL] RE: hi and request for Dr. Fauci this weekend on MSNBC

I am sure we can make one of these work – will let you know tomorrow.

We would do from the NBC Nebraska Ave NW Studio.

thx

Patricia L. Conrad  
Public Health Analyst and  
Special Assistant to the Director  
National Institute of Allergy and Infectious Diseases  
The National Institutes of Health  
31 Center Drive, MSC 2520 - Room 7A03  
Bethesda, Maryland 20892  
[REDACTED] (b) (6)  
301-496-4409 fax

**Disclaimer:**

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statement made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

---

**From:** Goldner, Shannah (NBCUniversal) <[shannah.goldner@nbcuni.com](mailto:shannah.goldner@nbcuni.com)>

**Sent:** Thursday, February 20, 2020 4:12 PM

**To:** Conrad, Patricia (NIH/NIAID) [E] <[REDACTED] (b) (6)>

**Cc:** Barasch, Kimberly (NIH/NIAID) [C] <[REDACTED] (b) (6)>; Deatrick, Elizabeth (NIH/NIAID) [C] <[REDACTED] (b) (6)>

**Subject:** hi and request for Dr. Fauci this weekend on MSNBC

**Importance:** High

Patricia, hi, I hope all is well with you.

Is Dr. Fauci available this weekend to be on MSNBC to discuss the latest re Corona virus - [https://www.washingtonpost.com/health/coronavirus-diamond-princess-cruise-americans/2020/02/20/b6f54cae-5279-11ea-b119-4faabac6674f\\_story.html](https://www.washingtonpost.com/health/coronavirus-diamond-princess-cruise-americans/2020/02/20/b6f54cae-5279-11ea-b119-4faabac6674f_story.html)

We'd like him on either on Saturday, in the 7:30am to 8am half hour, with Kendis Gibson/Cori Coffin, or on Sunday in the 12pm or 1pm hour with Alex Witt. Whatever day/hour that is good for him, we'll make work.

Thank you so much for your help in this matter.



All the best,

Shannah

Shannah Goldner

MSNBC

W: 212-664-1289

C: [REDACTED] (b) (6)

**From:** Fauci, Anthony (NIH/NIAID) [E]  
**Sent:** Sat, 22 Feb 2020 02:39:22 +0000  
**To:** Morens, David (NIH/NIAID) [E]  
**Subject:** FW: So what do you guys think ? (I no it's not influenza, but a lot of your 2007 conclusions seem very valid now...)

David:

Please respond to this person.

Thanks,

Tony

-----Original Message-----

**From:** [REDACTED] (b) (6)  
**Sent:** Friday, February 21, 2020 9:32 PM  
**To:** Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6)  
**Subject:** So what do you guys think ? (I no it's not influenza, but a lot of your 2007 conclusions seem very valid now...)

Dear David Morens, dear Anthony Fauci,

I realise it is not an influenza virus, but the outlook of your 2007 paper ("The 1918 Influenza Pandemic: Insights for the 21st Century") seems to me to be very valid for the current coronavirus outbreak. Or put differently - your statements and concerns from then mostly coincide with my thinking and worries now... :(.

So a question - what is your thinking now? Are the hospitals you're affiliated with hiring additional staff (yet)? Any personal preparations?

Good luck to you and all the best for those close to you, kind regards, Sean Scherer

P.S. I guess part of the the reason I'm asking is, because I (a non-institutionally affiliated biologist), am in touch with the university-hospital here ([REDACTED] (b) (6) Germany), but my concerns are so far falling on deaf ears... But also just reading the paper and seeing others come to the same conclusions - albeit on more theoretical grounds and multiple years ago - made me want to reach out. Plus I guess I'm simply curious about what you think !

**From:** (b) (6)  
**Sent:** Fri, 21 Feb 2020 14:38:56 -0500  
**To:** Billet, Courtney (NIH/NIAID) [E]  
**Cc:** Conrad, Patricia (NIH/NIAID) [E];Folkers, Greg (NIH/NIAID) [E]  
**Subject:** Re: Work related question

You are correct. No chance that I would accept. Thanks

On Feb 21, 2020, at 2:23 PM, Billet, Courtney (NIH/NIAID) [E]  
(b) (6) wrote:

In the interest of full disclosure: Stephanie (b) (6) used to work here at HHS and is now a VP with the American College of Preventive Medicine. For the life of me I couldn't see you saying yes to a weekend trip to Denver in May, and I would hate to have them waste their time sending an invite when they could be pursuing someone more likely to accept. Hope this is OK.

---

**From:** Billet, Courtney (NIH/NIAID) [E]  
**Sent:** Friday, February 21, 2020 2:18 PM  
**To:** Stephanie Marshall (b) (6) >  
**Subject:** RE: Work related question

Hi – good to hear from you! I hesitate to speak definitively for him and his scheduler, but to be perfectly honest I think it's really unlikely that'd he'd be able to accept a speaking invite for Denver. The schedule is insane for the foreseeable future and isn't letting up on the weekends. He's turning invitations down left and right, unfortunately – especially those involving travel!

---

**From:** Stephanie Marshall (b) (6)  
**Sent:** Friday, February 21, 2020 1:51 PM  
**To:** Billet, Courtney (NIH/NIAID) [E] (b) (6) >  
**Subject:** Work related question

Hi Courtney,

I hope you're doing well despite the ongoing craziness whether it's coronavirus or politics. Yikes, these are unsettled times.

I have a quick question for you. Our annual meeting is May 14 - 17 in Denver. Many of the sessions are in place but there's talk about doing a session around



coronavirus and inviting Dr. Fauci as the speaker. The meeting is a Thursday through Sunday and they're looking at inviting him to speak potentially on Sunday morning. Is this something he would even consider and would he commit this far out given everything that's going on? Any quick thoughts you might have would be helpful.

Thank you, thank you! Have a great weekend.

Stephanie

**From:** (b) (6)  
**Sent:** Fri, 21 Feb 2020 10:40:17 -0500  
**To:** Collins, Francis (NIH/OD) [E]  
**Cc:** Hallett, Adrienne (NIH/OD) [E]; Tabak, Lawrence (NIH/OD) [E]  
**Subject:** Re: FYI on Senate staff visit

Thanks, Francis.

On Feb 21, 2020, at 10:30 AM, Collins, Francis (NIH/OD) [E]

<(b) (6)>

Hi Tony,

I got asked by Alex Keenan what the NIH needs for the coronavirus response. I said that this had been looked at with great care by you and your staff. If you are asking me for technical assistance, I said, we need about (b) (5) for FY20-21, and more in the long run.

ASFR was in the room but did not have a visible seizure.

Just thought you'd want to know before you meet with the staffers later today.

FC

**From:** Fauci, Anthony (NIH/NIAID) [E]  
**Sent:** Fri, 21 Feb 2020 14:31:08 +0000  
**To:** Donna Jacobsen  
**Cc:** Conrad, Patricia (NIH/NIAID) [E]; Greg Folkers  
(b) (6); Marston, Hilary (NIH/NIAID) [E]  
**Subject:** RE: CROI COVID 19 Session; Tuesday March 10 lunch

Donna:

Thanks for the note. I will be able to provide a 15 minute video with slides that discusses the NIH/NIAID efforts to study the novel coronavirus and to develop countermeasures in the form of diagnostics, therapeutics, and vaccines. Your team can work with Patty Conrad, Hilary Marston and Greg Folkers on the logistics. In the meantime, we will prepare the video.

Best regards,

Tony

**Anthony S. Fauci, MD**  
Director  
National Institute of Allergy and Infectious Diseases  
Building 31, Room 7A-03  
31 Center Drive, MSC 2520  
National Institutes of Health  
Bethesda, MD 20892-2520  
Phone: (b) (6)  
FAX: (301) 496-4409  
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

---

**From:** Donna Jacobsen <djacobsen@iasusa.org>  
**Sent:** Thursday, February 20, 2020 8:53 PM  
**To:** Fauci, Anthony (NIH/NIAID) [E] (b) (6) >  
**Cc:** Conrad, Patricia (NIH/NIAID) [E] (b) (6)  
**Subject:** RE: CROI COVID 19 Session; Tuesday March 10 lunch  
**Importance:** High

Dear Dr Fauci:

We've had a lot of discussion around our COVID-19 session today. An idea that came up was possibly having you do something remotely. Either a live feed in from your office at approximately 1:05 PM to 1:20 PM EDT on Tuesday, March 10 if you have that time available, or have you send in a video recorded presentation a day or 2 before that we can show at the session. Having some way to communicate the



high priority NIH/NIAID has on developing a vaccine and treatment would help bring the content together.

We know this is likely not possible, with the very short notice and your even more tremendously busy schedule around all of this. But it's worth the ask.

Please let me know if you think either of these is possible. And Patty, sorry for butchering your email address earlier.

Best,

Donna

Donna M. Jacobsen  
Executive Director/President  
International Antiviral (formerly AIDS) Society-USA  
Executive Manager, CROI  
131 Steuart St, Ste 500  
San Francisco, CA 94105  
415-544-9400

<https://www.iasusa.org>



**About IAS–USA:** Established in 1992, the IAS–USA is a not-for-profit, professional education organization. The mission of the IAS-USA is to improve the prevention, treatment, care, and quality of life for people with or at risk of HIV, hepatitis C virus, or other viral infections through high-quality, relevant, balanced, and needs-oriented education and information for practitioners who are actively involved in medical care. The organization's educational activities are particularly intended to bridge clinical research and patient care.

**Confidentiality Notice:** This e-mail and its attachments may contain privileged and confidential information intended solely for the use of the IAS-USA and the recipient(s) named above. If you are not the intended recipient, or the employee or agent responsible for delivering this message to the intended recipients, you are hereby notified that any review, dissemination, distribution, printing, or copying of this e-mail message and/or any attachments is strictly prohibited. If you have received this transmission in error, please notify the sender immediately and permanently delete this e-mail and any attachments.

---

**From:** Fauci, Anthony (NIH/NIAID) [E] (b) (6)

**Sent:** Thursday, February 20, 2020 7:12 AM

**To:** Donna Jacobsen <[djacobsen@iasusa.org](mailto:djacobsen@iasusa.org)>  
**Cc:** (b) (6) 'Elaine J. Abrams, MD (b) (6)>; Sharon Hillier PhD (b) (6) Hoxie, James (b) (6); Benson, Connie (b) (6); Kevin Bowen <[kbowen@iasusa.org](mailto:kbowen@iasusa.org)>

**Subject:** RE: CROI COVID 19 Session; Tuesday March 10 lunch

Donna:

Thanks for the note. Unfortunately, I need to be in Washington, DC on March 10, and so I will regrettably have to decline your kind invitation. Thank you for thinking of me.

Best regards,

Tony

**Anthony S. Fauci, MD**  
Director  
National Institute of Allergy and Infectious Diseases  
Building 31, Room 7A-03  
31 Center Drive, MSC 2520  
National Institutes of Health  
Bethesda, MD 20892-2520  
Phone: (b) (6)  
FAX: (301) 496-4409  
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

---

**From:** Donna Jacobsen <[djacobsen@iasusa.org](mailto:djacobsen@iasusa.org)>  
**Sent:** Tuesday, February 18, 2020 8:09 PM  
**To:** Fauci, Anthony (NIH/NIAID) [E] (b) (6)  
**Cc:** (b) (6); 'Elaine J. Abrams, MD (b) (6)>; Sharon Hillier PhD (b) (6); Hoxie, James (b) (6); Benson, Connie (b) (6); Kevin Bowen <[kbowen@iasusa.org](mailto:kbowen@iasusa.org)>  
**Subject:** RE: CROI COVID 19 Session; Tuesday March 10 lunch

Dear Dr Fauci:

As I mentioned on the phone, we just today decided that we will have a special session on COVID 19 at CROI. It will be on Tuesday, March 10, during the lunch break; the initial general structure will be a 10- to 15- minute overview (CDC), a 25-min talk by Ralph Barac (UNC) about the virology of coronaviruses, and a 10- to 15-minute summary on what NIAID/NIH is doing and planning. We thought that this being



one of the first large medical conferences in infectious diseases this year, that we address COVID 19 at CROI

We know that this is terribly last minute, but the CROI Chairs and Foundation are hoping you are free to give the NIAID/NIH update. CROI is in Boston, March 8 to 11.

If you think you would be able to do this, we will send a more formal communication with details and work with Patty on the specifics. Thank you so much Dr Fauci; we hope you will be able to join us.

Best,

Donna

Donna M. Jacobsen  
Executive Director/President  
International Antiviral (formerly AIDS) Society-USA  
131 Steuart St, Ste 500  
San Francisco, CA 94105  
415-544-9400

<https://www.iasusa.org>



**About IAS–USA:** Established in 1992, the IAS–USA is a not-for-profit, professional education organization. The mission of the IAS-USA is to improve the prevention, treatment, care, and quality of life for people with or at risk of HIV, hepatitis C virus, or other viral infections through high-quality, relevant, balanced, and needs-oriented education and information for practitioners who are actively involved in medical care. The organization's educational activities are particularly intended to bridge clinical research and patient care.

**Confidentiality Notice:** This e-mail and its attachments may contain privileged and confidential information intended solely for the use of the IAS-USA and the recipient(s) named above. If you are not the intended recipient, or the employee or agent responsible for delivering this message to the intended recipients, you are hereby notified that any review, dissemination, distribution, printing, or copying of this e-mail message and/or any attachments is strictly prohibited. If you have received this transmission in error, please notify the sender immediately and permanently delete this e-mail and any attachments.



**From:** Fauci, Anthony (NIH/NIAID) [E]  
**Sent:** Fri, 21 Feb 2020 13:33:20 +0000  
**To:** Cassetti, Cristina (NIH/NIAID) [E]  
**Subject:** FW: FDA Request  
**Attachments:** FDA Clearance Letter.pdf, Nepal Corona Virus Paper.pdf

Please handle.

**Anthony S. Fauci, MD**  
**Director**  
**National Institute of Allergy and Infectious Diseases**  
**Building 31, Room 7A-03**  
**31 Center Drive, MSC 2520**  
**National Institutes of Health**  
**Bethesda, MD 20892-2520**

**Phone:** (b) (6)

**FAX:** (301) 496-4409

**E-mail:** (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

---

**From:** Jeff Fischer (b) (6)  
**Sent:** Friday, February 21, 2020 8:30 AM  
**To:** Messonnier, Nancy (CDC/DDID/NCIRD/OD) (b) (6); Khabbaz, Rima (CDC/DDID/NCEZID/OD) (b) (6); Fauci, Anthony (NIH/NIAID) [E] (b) (6)  
**Cc:** Chris Helm (b) (6) >  
**Subject:** FDA Request

Drs Messonnier, Khabbaz, and Fauci,

The Center for Devices and Radiological Health at the FDA suggested that we reach out to COVID-19 EUA developers to (b) (4)

(b) (4)

(b) (4)

Respectfully,

Jeff

Jeff Fischer  
President  
Longhorn Vaccines and Diagnostics LLC  
2 Bethesda Metro Center Suite 910  
Bethesda, MD 20814

(b) (6)

**From:** Fauci, Anthony (NIH/NIAID) [E]  
**Sent:** Fri, 21 Feb 2020 10:47:53 +0000  
**To:** Cassetti, Cristina (NIH/NIAID) [E]  
**Subject:** FW: Fwd:  
**Attachments:** Notes for NIH.docx

Please handle.

**From:** RICK SAWAYA [REDACTED] (b) (6) >  
**Sent:** Friday, February 21, 2020 1:48 AM  
**To:** Fauci, Anthony (NIH/NIAID) [E] <[REDACTED] (b) (6)>; Cassetti, Cristina (NIH/NIAID) [E]  
[REDACTED] (b) (6)  
**Subject:** Fwd:

2202020  
Dr. Fauci:

This is Dr. Rick Sawaya :

Dr. Tom Betz is [REDACTED] (b) (6) and his training is more in line with yours than mine. He submitted this mini-endorsement to you for me and my work. He has seen most of my works and the NIH data protocol from 2016-2017. I think his background gives credibility to my ideas and lends a public health opinion which I did not have until calling him.

Hope you enjoy this.  
I have treated cancers, herpes, acne easily with this stuff and honestly and confidentially it will do anything but your income tax.

Thanks, Rick Sawaya M.D.

[REDACTED] (b) (6)  
call between 10am and 10pm EST,

----- Forwarded message -----

**From:** Tom Betz [REDACTED] (b) (6)  
**Date:** Thu, Feb 20, 2020 at 10:32 PM  
**Subject:** Re:  
**To:** RICK SAWAYA [REDACTED] (b) (6)

Rick,

I am attaching suggested notes for NIH. They may think we're both crazy but I imagine you have already been down that road and I'm interested to see what happens. Hang in there,



Tom

On Tue, Feb 18, 2020 at 2:01 PM RICK SAWAYA [REDACTED] (b) (6) wrote:

THIS HAS THE CELL WITH LEARS SIGNATURE ABOVE IT  
AND A CYSTEINE RANDOM DIAGRAM

**From:** Fauci, Anthony (NIH/NIAID) [E]  
**Sent:** Fri, 21 Feb 2020 02:42:07 +0000  
**To:** NIAID OD AM  
**Subject:** FW: CROI COVID 19 Session; Tuesday March 10 lunch  
**Importance:** High

Let us discuss.

---

**From:** Donna Jacobsen <djacobsen@iasusa.org>  
**Sent:** Thursday, February 20, 2020 8:53 PM  
**To:** Fauci, Anthony (NIH/NIAID) [E] (b) (6) >  
**Cc:** Conrad, Patricia (NIH/NIAID) [E] (b) (6) >  
**Subject:** RE: CROI COVID 19 Session; Tuesday March 10 lunch  
**Importance:** High

Dear Dr Fauci:

We've had a lot of discussion around our COVID-19 session today. An idea that came up was possibly having you do something remotely. Either a live feed in from your office at approximately 1:05 PM to 1:20 PM EDT on Tuesday, March 10 if you have that time available, or have you send in a video recorded presentation a day or 2 before that we can show at the session. Having some way to communicate the high priority NIH/NIAID has on developing a vaccine and treatment would help bring the content together.

We know this is likely not possible, with the very short notice and your even more tremendously busy schedule around all of this. But it's worth the ask.

Please let me know if you think either of these is possible. And Patty, sorry for butchering your email address earlier.

Best,

Donna

Donna M. Jacobsen  
Executive Director/President  
International Antiviral (formerly AIDS) Society-USA  
Executive Manager, CROI  
131 Steuart St, Ste 500  
San Francisco, CA 94105  
415-544-9400

<https://www.iasusa.org>



**About IAS–USA:** Established in 1992, the IAS–USA is a not-for-profit, professional education organization. The mission of the IAS-USA is to improve the prevention, treatment, care, and quality of life for people with or at risk of HIV, hepatitis C virus, or other viral infections through high-quality, relevant, balanced, and needs-oriented education and information for practitioners who are actively involved in medical care. The organization’s educational activities are particularly intended to bridge clinical research and patient care.

**Confidentiality Notice:** This e-mail and its attachments may contain privileged and confidential information intended solely for the use of the IAS-USA and the recipient(s) named above. If you are not the intended recipient, or the employee or agent responsible for delivering this message to the intended recipients, you are hereby notified that any review, dissemination, distribution, printing, or copying of this e-mail message and/or any attachments is strictly prohibited. If you have received this transmission in error, please notify the sender immediately and permanently delete this e-mail and any attachments.

---

**From:** Fauci, Anthony (NIH/NIAID) [E] (b) (6)  
**Sent:** Thursday, February 20, 2020 7:12 AM  
**To:** Donna Jacobsen <[djacobsen@iasusa.org](mailto:djacobsen@iasusa.org)>  
**Cc:** (b) (6) 'Elaine J. Abrams, MD' (b) (6)  
Sharon Hillier PhD (b) (6); Hoxie, James  
<(b) (6)>; Benson, Connie (b) (6); Kevin Bowen  
<[kbowen@iasusa.org](mailto:kbowen@iasusa.org)>  
**Subject:** RE: CROI COVID 19 Session; Tuesday March 10 lunch

Donna:

Thanks for the note. Unfortunately, I need to be in Washington, DC on March 10, and so I will regrettably have to decline your kind invitation. Thank you for thinking of me.

Best regards,

Tony

Anthony S. Fauci, MD  
Director  
National Institute of Allergy and Infectious Diseases  
Building 31, Room 7A-03  
31 Center Drive, MSC 2520  
National Institutes of Health  
Bethesda, MD 20892-2520  
Phone: (b) (6)



FAX: (301) 496-4409

E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

---

**From:** Donna Jacobsen <[djacobsen@iasusa.org](mailto:djacobsen@iasusa.org)>

**Sent:** Tuesday, February 18, 2020 8:09 PM

**To:** Fauci, Anthony (NIH/NIAID) [E] (b) (6) >

**Cc:** (b) (6) Elaine J. Abrams, MD (b) (6)

Sharon Hillier PhD (b) (6); Hoxie, James

(b) (6); Benson, Connie (b) (6); Kevin Bowen

<[kbowen@iasusa.org](mailto:kbowen@iasusa.org)>

**Subject:** RE: CROI COVID 19 Session; Tuesday March 10 lunch

Dear Dr Fauci:

As I mentioned on the phone, we just today decided that we will have a special session on COVID 19 at CROI. It will be on Tuesday, March 10, during the lunch break; the initial general structure will be a 10- to 15- minute overview (CDC), a 25-min talk by Ralph Barac (UNC) about the virology of coronaviruses, and a 10- to 15-minute summary on what NIAID/NIH is doing and planning. We thought that this being one of the first large medical conferences in infectious diseases this year, that we address COVID 19 at CROI

We know that this is terribly last minute, but the CROI Chairs and Foundation are hoping you are free to give the NIAID/NIH update. CROI is in Boston, March 8 to 11.

If you think you would be able to do this, we will send a more formal communication with details and work with Patty on the specifics. Thank you so much Dr Fauci; we hope you will be able to join us.

Best,

Donna

Donna M. Jacobsen  
Executive Director/President  
International Antiviral (formerly AIDS) Society-USA  
131 Steuart St, Ste 500  
San Francisco, CA 94105  
415-544-9400

<https://www.iasusa.org>





**About IAS–USA:** Established in 1992, the IAS–USA is a not-for-profit, professional education organization. The mission of the IAS-USA is to improve the prevention, treatment, care, and quality of life for people with or at risk of HIV, hepatitis C virus, or other viral infections through high-quality, relevant, balanced, and needs-oriented education and information for practitioners who are actively involved in medical care. The organization's educational activities are particularly intended to bridge clinical research and patient care.

**Confidentiality Notice:** This e-mail and its attachments may contain privileged and confidential information intended solely for the use of the IAS-USA and the recipient(s) named above. If you are not the intended recipient, or the employee or agent responsible for delivering this message to the intended recipients, you are hereby notified that any review, dissemination, distribution, printing, or copying of this e-mail message and/or any attachments is strictly prohibited. If you have received this transmission in error, please notify the sender immediately and permanently delete this e-mail and any attachments.

**From:** Fauci, Anthony (NIH/NIAID) [E]  
**Sent:** Fri, 21 Feb 2020 01:47:03 +0000  
**To:** McNeil Jr, Donald G  
**Subject:** RE: question re the WashPost story

Donald:

You know that I always answer your calls and e-mails, but this one I want to stay away from.  
Sorry.  
Best,  
Tony

**From:** McNeil Jr, Donald G <mcneil@nytimes.com>  
**Sent:** Thursday, February 20, 2020 4:51 PM  
**To:** Fauci, Anthony (NIH/NIAID) [E] (b) (6)  
**Subject:** Re: question re the WashPost story

Now that I've had a chance to read the whole story -- after editors finished whirling -- I see it also contains these grafs:

Are they accurate?

Thanks

During one call, the CDC's principal deputy director, **Anne Schuchat**, argued against taking the infected Americans on the plane, according to two participants. She noted the U.S. government had already told passengers they would not be evacuated with anyone who was infected or showed symptoms. She was also concerned about infection control. **Anthony Fauci**, head of the National Institute of Allergy and Infectious Diseases, who was also on the calls, **recalled** saying her points were valid and should be considered. But **Robert Kadlec**, assistant secretary for preparedness and response for the Department of Health and Human Services and a member of the coronavirus task force, pushed back: Officials had already prepared the plane to handle passengers who might develop symptoms on the long flight, he argued. The two Boeing 747s had 18 seats cordoned off with 10-foot-high plastic on all four sides. Infectious disease doctors would also be onboard.

On Thu, Feb 20, 2020 at 4:24 PM McNeil Jr, Donald G <[mcneil@nytimes.com](mailto:mcneil@nytimes.com)> wrote:

Hi, Tony:

The Washington Post has just put up a story saying that the 14 infected passengers on the buses containing 238 American passengers from the Diamond Princess were flown home AGAINST the CDC's advice. And that the States Department overruled the CDC on this.

Can you confirm whether that's true?



Thanks...

Donald

Story contains these crucial grafs:

In Washington, where it was still Sunday afternoon, a fierce debate broke out: The State Department and a top Trump administration health official wanted to forge ahead. The infected passengers had no symptoms and could be segregated on the plane in a plastic-lined enclosure. But officials at the Centers for Disease Control and Prevention disagreed, contending they could still spread the virus. The CDC believed the 14 should not be flown back with uninfected passengers.

“It was like the worst nightmare,” said a senior U.S. official involved in the decision, speaking on the condition of anonymity to describe private conversations. “Quite frankly, the alternative could have been pulling grandma out in the pouring rain, and that would have been bad, too.”

--

**Donald G. McNeil Jr.**  
**Science Correspondent**  
*The New York Times*

Tel: +1 212 556 1142  
[mneil@nytimes.com](mailto:mneil@nytimes.com)

Articles: <https://www.nytimes.com/by/donald-g-mcneil-jr>

**From:** Fauci, Anthony (NIH/NIAID) [E]  
**Sent:** Fri, 21 Feb 2020 00:13:55 +0000  
**To:** Richard Allen Johnson  
**Subject:** RE: 02.20.2020 Thursday

Dick:

Thanks for the note. Always good to hear from you.

Best,  
Tony

Anthony S. Fauci, MD  
Director  
National Institute of Allergy and Infectious Diseases  
Building 31, Room 7A-03  
31 Center Drive, MSC 2520  
National Institutes of Health  
Bethesda, MD 20892-2520  
Phone: (b) (6)  
FAX: (301) 496-4409  
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

**From:** Richard Allen Johnson (b) (6)  
**Sent:** Thursday, February 20, 2020 6:57 PM  
**To:** Fauci, Anthony (NIH/NIAID) [E] (b) (6); Sandra Goldstein (b) (6)  
**Subject:** 02.20.2020 Thursday

Hi, Tony,

(b) (6) this week.

We watched a life size ASF as you discussed and reassured us about Covid-19. You are simply the best. Were you running for president, I am sure that you would win the yote.

Don't forget our lunch in Boston.

Best,  
Dick

**From:** Fauci, Anthony (NIH/NIAID) [E]  
**Sent:** Thu, 20 Feb 2020 23:48:29 +0000  
**To:** Conrad, Patricia (NIH/NIAID) [E]  
**Cc:** Billet, Courtney (NIH/NIAID) [E]  
**Subject:** FW: Urgent- Phone Interview Request on Coronavirus

Done!

**Anthony S. Fauci, MD**  
Director  
National Institute of Allergy and Infectious Diseases  
Building 31, Room 7A-03  
31 Center Drive, MSC 2520  
National Institutes of Health  
Bethesda, MD 20892-2520  
Phone: (b) (6)  
FAX: (301) 496-4409  
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

---

**From:** Qi Zhang <qizhang@caixin.com>  
**Sent:** Thursday, February 20, 2020 3:16 PM  
**To:** Fauci, Anthony (NIH/NIAID) [E] (b) (6)>  
**Subject:** Urgent- Phone Interview Request on Coronavirus

Dear Dr. Fauci,

Good afternoon. I am Olivia Zhang with Caixin Media, which is the front-liner of the Coronavirus reporting in China. We spoke at the very beginning of the virus and I wanted to talk to you regarding the latest situation, especially from test, treatment point of view. I also left you a voice message. Feel free to call me via (b) (6) whenever you're free.

I look forward to hearing from you.

Best,  
Olivia

**Qi ZHANG (Olivia)**  
U.S. Correspondent  
Caixin Media Company Limited



Email: [qizhang@caixin.com](mailto:qizhang@caixin.com)

Mobile: + [REDACTED] (b) (6)

Twitter: @zhang\_qiii

[www.caixin.com](http://www.caixin.com) | [caixinglobal.com](http://caixinglobal.com)

**From:** Fauci, Anthony (NIH/NIAID) [E]  
**Sent:** Thu, 20 Feb 2020 23:28:04 +0000  
**To:** Achenbach, Joel  
**Subject:** RE: quick question: when does an epidemic become a "pandemic" officially?

It is impossible to predict at this point if the current outbreak will progress to a true pandemic. The future of this outbreak and whether it will progress to a pandemic will be determined by two factors: 1) the degree to which China controls infections in China, which will ultimately impact how many infections leak out to other countries in the world. 2) The success or not of other countries that have received travel-related cases from China in preventing the development of sustained transmission of infections in their own country. If these other countries are successful in containing the transmissions, then a pandemic will be avoided. If a large number of countries are unsuccessful in preventing sustained multi-generation transmissions, then we could witness the next pandemic.

**Anthony S. Fauci, MD**  
Director  
National Institute of Allergy and Infectious Diseases  
Building 31, Room 7A-03  
31 Center Drive, MSC 2520  
National Institutes of Health  
Bethesda, MD 20892-2520  
Phone: (b) (6)  
FAX: (301) 496-4409  
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

---

**From:** Achenbach, Joel <Joel.Achenbach@washpost.com>  
**Sent:** Thursday, February 20, 2020 6:11 PM  
**To:** Fauci, Anthony (NIH/NIAID) [E] (b) (6)>  
**Subject:** RE: quick question: when does an epidemic become a "pandemic" officially?

Oh....and...the big question: How likely is it that covid-19 will become a pandemic? Would love an on-the-record assessment. Thanks...joel

---

**From:** Fauci, Anthony (NIH/NIAID) [E] (b) (6)>  
**Sent:** Thursday, February 20, 2020 6:06 PM  
**To:** Achenbach, Joel <[Joel.Achenbach@washpost.com](mailto:Joel.Achenbach@washpost.com)>  
**Subject:** RE: quick question: when does an epidemic become a "pandemic" officially?

**CAUTION: EXTERNAL SENDER**

Joel:

There are many iterations of the definition of a “pandemic”. However, one that I use that is simple and understandable is as follows: An outbreak of a serious infectious disease with substantial global health consequences (usually one that has never before been experienced by the human population) that is transmitted readily from person to person and where there is sustained transmission (i.e. multiple generations of person to person to person) in multiple countries and regions of the world. In this regard, the coronavirus outbreak in China is an “epidemic” in China, but it is not yet a pandemic since there is not “sustained” person to person transmission throughout the world. There are infections in other countries (more than 25 countries), but these started as travel related cases from China and although there are several human to human infections in these other countries, these infections have not yet been “sustained”. If we start seeing sustained, multiple generations of transmissions in many countries throughout the world, then the outbreak will have progressed to fill the criteria of a true pandemic.

Hope that this is helpful.

Best regards,  
Tony

Anthony S. Fauci, MD  
Director  
National Institute of Allergy and Infectious Diseases  
Building 31, Room 7A-03  
31 Center Drive, MSC 2520  
National Institutes of Health  
Bethesda, MD 20892-2520  
Phone: (b) (6)  
FAX: (301) 496-4409  
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

---

**From:** Achenbach, Joel <[Joel.Achenbach@washpost.com](mailto:Joel.Achenbach@washpost.com)>

**Sent:** Thursday, February 20, 2020 5:51 PM



**To:** Fauci, Anthony (NIH/NIAID) [E] <[REDACTED] (b) (6)>

**Subject:** quick question: when does an epidemic become a "pandemic" officially?

Dear Tony Fauci:

Hi! Busy times. Hope you are well. Can you explain to me how we will know if and when covid-19 has become pandemic, versus whatever you'd call the current situation? Just in general, what's the definition of a pandemic?

Thank you...best, Joel

(and thanks for calling me back last weekend, sorry I missed you)

**From:** Fauci, Anthony (NIH/NIAID) [E]  
**Sent:** Thu, 20 Feb 2020 16:45:39 +0000  
**To:** Michael Gerson  
**Subject:** RE: Tony, I'm still working on this, but need your reaction  
**Attachments:** Gerson with minor Fauci edits.docx

Mike:

Thanks for sending this. It looks good. I have copied it to a WORD document and have made some minor suggested edits for your consideration.

Best regards,

Tony

Anthony S. Fauci, MD  
Director  
National Institute of Allergy and Infectious Diseases  
Building 31, Room 7A-03  
31 Center Drive, MSC 2520  
National Institutes of Health  
Bethesda, MD 20892-2520  
Phone: (b) (6)  
FAX: (301) 496-4409  
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

---

**From:** Michael Gerson (b) (6) >  
**Sent:** Thursday, February 20, 2020 11:04 AM  
**To:** Fauci, Anthony (NIH/NIAID) [E] (b) (6)  
**Subject:** Tony, I'm still working on this, but need your reaction

Meanwhile, on the other side of the earth, there have been 73,000 cases of coronavirus and more than 2000 deaths. This leaves American health experts hoping that the number of infections has been dramatically underreported.

That is not a typo. If the current numbers are close to accurate, it indicates a coronavirus mortality rate upwards of 2 percent. The morality rate for the seasonable flu is generally .1 percent. The mortality rate for pandemic flu is .3 percent. The particularly deadly flu pandemic of 1918 –

which took the lives of more than 100 million people around the world – had a mortality rate of 1.8 to 2 percent.

So, if 2000 deaths is the numerator, scientists hope that the denominator is actually much larger. And that is probable, given the likelihood that there are many more people who have the infection but don't know it, or are not showing symptoms.

The good news? The outbreak started in a single location and seems largely contained there. There have been several hundred cases in more than 25 countries outside of China. But the overwhelming majority have been travel related. The containment measures of Singapore, Hong Kong and Japan – which have the most cases – seem to have been successful. Of the 15 American cases (before the arrival of the cruise ship passengers), 13 are travel related. The two others are spouses of people in that group. We still have not seen widespread, sustained transmission from person to person outside of China.

The Chinese reaction to the virus has shown the weaknesses and advantages of authoritarianism. The immediate response of a system built on fear is to a problem like this one is denial and deception. No one wants to carry bad news. So local Chinese officials spent the first week of the outbreak – as the disease was spreading under the radar – insisting that the transmission of the virus was all animal to human.

But only in a society like China could you have the effective lockdown of 50 million people, including the entire city of Wuhan, to slow the spread of the disease. Public health officials in most places – who are required to balance health needs with civil liberties – would not even consider such a measure. Yet it appears to be working.

The danger? “All that is needed is for a few countries in the developing world that can't contain the coronavirus,” Tony Fauci told me. “This could be the second wave of the pandemic.”

Pandemic diseases tend to attack the weakest links – the most vulnerable health systems – in the global chain. If there is sustained transmission in those places, says Fauci, “even countries with best practices will suffer.” Countries in Africa are of particular concern. There are millions of Chinese in Africa, and many Africans study in China. Countries such as Ethiopia, Senegal and South Africa seem to be doing a good job at testing random samples for coronavirus in key cities. But Liberia? Guinea? Sierra Leone?

Seldom has there been a stronger argument for American global engagement to strengthen African health systems, which constitute part of own immune system against pandemics. Seldom has there been a better



argument to abandon “America First” posturing and to recognize that our own fate is closely tied to the fate of other nations.

Much about the future course of the disease depends on the answer to a scientific question: Is someone who has the virus but lacks symptoms – or has symptoms so mild they hardly notice – capable of transmitting the virus to others? “It looks like the answer is yes,” says Fauci. Which would make the virus far harder to control.

“We may find that the virus is highly transmissible, but less lethal than we thought in the beginning,” Fauci told me. In this case, the danger would be similar to a particularly bad influenza. And the outbreaks could be seasonal, like the flu as well. “I would not be surprised if that happened,” Fauci concluded.

**From:** Fauci, Anthony (NIH/NIAID) [E]  
**Sent:** Thu, 20 Feb 2020 15:15:05 +0000  
**To:** Cassetti, Cristina (NIH/NIAID) [E]  
**Subject:** FW: inquiry/suggestion re Corona virus->

Please handle.

**Anthony S. Fauci, MD**  
Director  
National Institute of Allergy and Infectious Diseases  
Building 31, Room 7A-03  
31 Center Drive, MSC 2520  
National Institutes of Health  
Bethesda, MD 20892-2520  
Phone: (b) (6)  
FAX: (301) 496-4409  
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

**From:** Alan DiCara (b) (6)  
**Sent:** Wednesday, February 19, 2020 8:19 PM  
**To:** Fauci, Anthony (NIH/NIAID) [E] (b) (6)  
**Cc:** NIAID Ocpostoffice (NIH/NIAID) <OCPOSTOFFICE@niaid.nih.gov>  
**Subject:** inquiry/suggestion re Corona virus->

2.19.2020

Dear Dr Fauci,

Thanks so much for being who you are and for dedicating your life to protecting all of us. I write because I saw your interview on PBS tonight and had a question pertaining to denominators and numerators. Please know that I profess absolutely no expertise in areas pertaining to biology nor medicine nor disease and while I understood and agree with your estimation that the fatality rate of the Corona virus to date may be somewhat inflated of the number of cases is understated, I have a related

question for you regarding info I was able to find at this site <https://www.worldometers.info/coronavirus/>

Regarding data this site reports, among many things, and as one scrolls down, that the 'number of active cases' reported today is 57,228 and the number of these that are 'serious or critical' is 12,064. In a worst case scenario, and taking the 12,064 as the numerator and dividing it by a denominator of 57,228, we get 21.08, or about 21%, much higher than the 1% based on total deaths over total cases so far. Of course this is not fair but my question is this: can we know **better** how many of the patients (cases) who are 'serious or critical' and still being treated will recover?

Thanks much for any reply-  
Alan DiCara, Winsted, CT



**From:** Fauci, Anthony (NIH/NIAID) [E]  
**Sent:** Thu, 20 Feb 2020 12:39:25 +0000  
**To:** David Katz  
**Subject:** RE: CoronaVirus Epidemic -- a Thought

David:

Thanks for the note. I hope that all is well with you. Although allogeneic/semi-allogeneic blood transfusions could be an interesting approach to serious COVID-19 disease, there are a number of existing drugs such as remdesivir (nucleotide analogue) and Kaletra (protease inhibitor) that have some pre-clinical activity against the virus and these are now being tested in randomized clinical trials.

Best regards,

Tony

**Anthony S. Fauci, MD**  
Director  
National Institute of Allergy and Infectious Diseases  
Building 31, Room 7A-03  
31 Center Drive, MSC 2520  
National Institutes of Health  
Bethesda, MD 20892-2520  
Phone: (b) (6)  
FAX: (301) 496-4409  
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

**From:** David Katz (b) (6)  
**Sent:** Wednesday, February 19, 2020 6:02 PM  
**To:** Fauci, Anthony (NIH/NIAID) [E] (b) (6)>  
**Subject:** CoronaVirus Epidemic -- a Thought

Dear Tony,

It has been some time since we last spoke, but this current catastrophe has provoked my thinking about possible therapeutic interventions that could be immediately employed -- in advance of therapies/vaccines that will take

many months to create. And I need to share those thoughts with you.

My suggestion is to treat actively-infected, and acutely ill, patients (under carefully controlled procedures) with allogeneic/ semi-allogeneic blood transfusions. The resulting GVHD response should theoretically combat, and eradicate the viral infection.

I look forward to your thoughts on this suggestion.

With best wishes to you and your family,

David

**From:** Fauci, Anthony (NIH/NIAID) [E]  
**Sent:** Thu, 20 Feb 2020 10:51:23 +0000  
**To:** Conrad, Patricia (NIH/NIAID) [E]  
**Cc:** Marston, Hilary (NIH/NIAID) [E]  
**Subject:** FW: GPMB: MESSAGE ON BEHALF OF THE CO-CHAIRS: PROPOSED BOARD TELECONFERENCE TODAY

FYI

---

**From:** Amelie RIOUX (b) (6) >  
**Sent:** Thursday, February 20, 2020 2:00 AM  
**To:** As Sy (b) (6) >; Gro Harlem Brundtland <(b) (6)>; 'Dzau Victor' (b) (6); Chris Elias (b) (6); Fauci, Anthony (NIH/NIAID) [E] (b) (6); Fore Henrietta (b) (6) >; Gao Fu (b) (6); Gashumba Diane (b) (6); Ilona Kickbusch (b) (6); Suzuki Yasuhiro (b) (6); Vega Morales Jeanette (b) (6); VijayRaghavan Krishnaswamy (b) (6) >; Skvortsova Veronika (b) (6)  
**Cc:** (b) (6) Tore Godal (b) (6); Godal, Tore (b) (6)  
**Subject:** GPMB: MESSAGE ON BEHALF OF THE CO-CHAIRS: PROPOSED BOARD TELECONFERENCE TODAY  
**Importance:** High

MESSAGE ON BEHALF OF THE GPMB CO-CHAIRS DR BRUNDTLAND AND MR SY

Dear Board Members,

We would like to hold a teleconference of the Board **today, 20 February at 13:00 Geneva time.**

The agenda for the call would be as follows:

- Short update and stock taking on the coronavirus outbreak;
- Functioning of the Secretariat and improving effectiveness of the Board;
- Way forward

Please note that this call would be a **closed discussion, for Board members only.**

We would appreciate if you could confirm your participation to Amélie Rioux (at (b) (6))

We will share with you shortly the call-in details.

Thank you for your support and continued engagement. We look forward to the call.

With kind regards,

Gro and As



**From:** Fauci, Anthony (NIH/NIAID) [E]  
**Sent:** Thu, 20 Feb 2020 03:43:40 +0000  
**To:** Sharon Rockefeller  
**Subject:** RE: This evening's broadcast

Thanks, Sharon. It is always a pleasure to be on the PBS NewsHour. They are high on honesty and integrity.

Best regards,  
Tony

---

**From:** Sharon Rockefeller <srockefeller@weta.org>  
**Sent:** Wednesday, February 19, 2020 8:33 PM  
**To:** Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6)  
**Subject:** This evening's broadcast

Dear Dr. Fauci,

Thank you, once again, for appearing on the PBS NewsHour and for treating so many Coronavirus patients. Your gift of calm and clear explanations to normal people is unparalleled. Please do not exhaust yourself as you help so many others. [REDACTED] (b) (6).

Very sincerely,  
Sharon

Sent from my iPhone

**From:** Fauci, Anthony (NIH/NIAID) [E]  
**Sent:** Thu, 20 Feb 2020 00:54:10 +0000  
**To:** Crawford, Chase (NIH/NIAID) [E]  
**Cc:** Billet, Courtney (NIH/NIAID) [E];Folkers, Greg (NIH/NIAID) [E];Conrad, Patricia (NIH/NIAID) [E];Haskins, Melinda (NIH/NIAID) [E];Selgrade, Sara (NIH/NIAID) [E]  
**Subject:** RE: Requesting your assistance: Draft NIAID Insert for Upcoming Coronavirus Hearings  
**Attachments:** Draft NIAID insert for COVID-19 hearings\_to ASF - with Fauci tracked edits.docx

Here it is. Thanks.

Anthony S. Fauci, MD  
Director  
National Institute of Allergy and Infectious Diseases  
Building 31, Room 7A-03  
31 Center Drive, MSC 2520  
National Institutes of Health  
Bethesda, MD 20892-2520  
Phone: (b) (6)  
FAX: (301) 496-4409  
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

---

**From:** Crawford, Chase (NIH/NIAID) [E] (b) (6)  
**Sent:** Wednesday, February 19, 2020 6:16 PM  
**To:** Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>  
**Cc:** Billet, Courtney (NIH/NIAID) [E] (b) (6)>; Folkers, Greg (NIH/NIAID) [E] (b) (6)>; Conrad, Patricia (NIH/NIAID) [E] (b) (6); Haskins, Melinda (NIH/NIAID) [E] (b) (6)>; Selgrade, Sara (NIH/NIAID) [E] (b) (6)>  
**Subject:** Requesting your assistance: Draft NIAID Insert for Upcoming Coronavirus Hearings

Dr. Fauci:

In preparation for the upcoming COVID-19 hearings of the House Committee on Energy and Commerce Health Subcommittee and the Senate Committee on Health, Education, Labor and Pensions, we have drafted the attached NIAID insert for inclusion in the combined HHS statement for the record. The Department plans to use the same combined statement for both the House and Senate hearings.

The attached draft has been reviewed by the Divisions and Drs. Harper, Eisinger, Lerner, and Marston, as well as Courtney Billet, Martin Johnson, Greg Folkers, and Laurie Doepel.

The Department has asked to receive your statement by COB tomorrow, Feb. 20th.

Thank you for your help.

Chase

**Chase Crawford, D.V.M., M.S.**

Public Health Analyst

Legislative Affairs and Correspondence Management Branch

Office of Communications and Government Relations

NIAID/NIH/DHHS

Bldg. 31, Room 7A17, MSC 2520

Bethesda, MD 20892-2520

(b) (6)

**Disclaimer:**

*The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases shall not accept liability for any statements made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.*



**From:** Fauci, Anthony (NIH/NIAID) [E]  
**Sent:** Wed, 19 Feb 2020 23:03:23 +0000  
**To:** Cassetti, Cristina (NIH/NIAID) [E]  
**Subject:** FW: BioCentury coverage of mAbs to treat COVID-19

Please handle.

**Anthony S. Fauci, MD**  
Director  
National Institute of Allergy and Infectious Diseases  
Building 31, Room 7A-03  
31 Center Drive, MSC 2520  
National Institutes of Health  
Bethesda, MD 20892-2520  
Phone: (b) (6)  
FAX: (301) 496-4409  
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

---

**From:** Karen Tkach Tuzman <ktkach@biocentury.com>  
**Sent:** Wednesday, February 19, 2020 5:56 PM  
**To:** Fauci, Anthony (NIH/NIAID) [E] (b) (6)  
**Cc:** Conrad, Patricia (NIH/NIAID) [E] (b) (6)  
**Subject:** BioCentury coverage of mAbs to treat COVID-19  
**Importance:** High

Dear Dr. Fauci,

I hope all is well. BioCentury is doing a roundup of companies and institutions developing antibodies against the SARS-CoV-2 virus to treat patients with COVID-19. Since you told my colleague Steve Usdin NIAID is developing its own mAbs against the virus, we'd like to include information about that program in our roundup.

Would you or one of your colleagues be able to answer the following questions? Any information you could share by 5 PM Pacific Time on Thursday, Feb. 20 would be greatly appreciated.

1. Are your mAb candidates being developed against specific targets on SARS-CoV-2? If so, what are those targets?
2. What platforms or processes are you using to identify mAb candidates?
3. Do you have multiple mAb programs against SARS-CoV-2 proceeding in parallel, and if so, how are they distinguished?

4. What is that status of each of your mAb programs? For example, have you nominated any lead candidates, are you awaiting patient samples, etc.?
5. Do you have any metrics on lead candidates available yet, such as neutralization titers? If so, what are they?

All the best,  
Karen

Karen Tkach Tuzman, Ph.D.  
Head, Discovery & Preclinical Development  
Associate Editor, BioCentury Inc.  
650-595-5333 x 144 (office)  
[www.biocentury.com](http://www.biocentury.com)

Notice: This communication (including any attachments) constitutes an electronic communication within the meaning of the Electronic Communications Privacy Act, 18 USC 2510, and its disclosure is strictly limited to the recipient(s) intended by the sender of this message. This communication (including any attachments) contains proprietary information, is protected under U.S. and foreign copyright and other intellectual property law, and may contain confidential material for the sole use of the intended recipient. Any unauthorized review, use, disclosure, dissemination, copying or distribution of this communication (including any attachments), or any of their respective contents, is strictly prohibited. If you are not the intended recipient, please contact the sender by return email and destroy all copies of the original message.

**From:** Fauci, Anthony (NIH/NIAID) [E]  
**Sent:** Wed, 19 Feb 2020 20:27:04 +0000  
**To:** Conrad, Patricia (NIH/NIAID) [E]  
**Cc:** Greg Folkers (b) (6)  
**Subject:** FW: Invitation to Speak  
**Attachments:** Invitation\_Dr. Anthony Fauci.pdf

Patty/Greg:  
Let us discuss.  
ASF

**Anthony S. Fauci, MD**  
Director  
National Institute of Allergy and Infectious Diseases  
Building 31, Room 7A-03  
31 Center Drive, MSC 2520  
National Institutes of Health  
Bethesda, MD 20892-2520  
Phone: (b) (6)  
FAX: (301) 496-4409  
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

---

**From:** Crow, Hilary <HCrow@USChamber.com>  
**Sent:** Wednesday, February 19, 2020 12:35 PM  
**To:** Fauci, Anthony (NIH/NIAID) [E] (b) (6)>  
**Subject:** Invitation to Speak

Dear Dr. Fauci,

I'm writing to share the attached invitation with you to speak at the U.S. Chamber Foundation's program on March 10 on the future of medicine.

Our audience of CEOs, market leaders, and opinion leaders would be thrilled to learn more about your perspective on the future of medicine, current issues like the Coronavirus, and future challenges in health and medicine.

Please let me know if you have any questions. I'm happy to schedule a quick call to provide more detail over the phone with you or someone on your team.

I hope you will be able to join us.



Best,  
Hilary

**Hilary Crow**

Executive Director, Programs  
U.S. Chamber of Commerce Foundation  
1615 H Street, NW | Washington, DC | 20062-2000  
Office: 202.463.5710  
Mobile: (b) (6)



**U.S. Chamber of Commerce Foundation**

[www.uschamberfoundation.org](http://www.uschamberfoundation.org)



**From:** Fauci, Anthony (NIH/NIAID) [E]  
**Sent:** Wed, 19 Feb 2020 16:51:27 +0000  
**To:** Marston, Hilary (NIH/NIAID) [E]  
**Cc:** Conrad, Patricia (NIH/NIAID) [E];Folkers, Greg (NIH/NIAID) [E];Handley, Gray (NIH/NIAID) [E]  
**Subject:** RE: Invitation to the Consultation on Financing Coronavirus Disease 2019 (COVID-19) Vaccine Development | Thursday, February 20, 2020 | 9:30am to 1:30pm | World Bank Headquarters, Washington DC

If they accept two people, you should go with Gray. Obviously, you should make no commitments and when asked about policy issues, say that you will convey to me and we will get back to them.

**Anthony S. Fauci, MD**  
Director  
National Institute of Allergy and Infectious Diseases  
Building 31, Room 7A-03  
31 Center Drive, MSC 2520  
National Institutes of Health  
Bethesda, MD 20892-2520  
Phone: (b) (6)  
FAX: (301) 496-4409  
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

---

**From:** Marston, Hilary (NIH/NIAID) [E] (b) (6)>  
**Sent:** Wednesday, February 19, 2020 10:09 AM  
**To:** Fauci, Anthony (NIH/NIAID) [E] (b) (6)  
**Cc:** Conrad, Patricia (NIH/NIAID) [E] (b) (6); Folkers, Greg (NIH/NIAID) [E] (b) (6); Handley, Gray (NIH/NIAID) [E] (b) (6)  
**Subject:** Re: Invitation to the Consultation on Financing Coronavirus Disease 2019 (COVID-19) Vaccine Development | Thursday, February 20, 2020 | 9:30am to 1:30pm | World Bank Headquarters, Washington DC

Have you had a chance to discuss this world bank conference? You, Cliff and Libby received invites. As Gray has mentioned, this is a pledging conference, so we will need to be prepared to address funding (the person that attends would need to be in sync with you on that). Obviously Cliff is on travel. Who would you like to have at the conference, if anyone?

-hilary

---

**From:** Anthony Fauci <[REDACTED] (b) (6)>

**Date:** Friday, February 14, 2020 at 9:25 PM

**To:** NIAID AM <[NIAIDODAM@niaid.nih.gov](mailto:NIAIDODAM@niaid.nih.gov)>

**Subject:** FW: Invitation to the Consultation on Financing Coronavirus Disease 2019 (COVID-19) Vaccine Development | Thursday, February 20, 2020 | 9:30am to 1:30pm | World Bank Headquarters, Washington DC

Let us discuss.

---

**From:** Feng Zhao <[fzhao@worldbank.org](mailto:fzhao@worldbank.org)>

**Sent:** Friday, February 14, 2020 5:22 PM

**To:** Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6)

**Cc:** [REDACTED] (b) (6); Mukesh Chawla <[mchawla@worldbank.org](mailto:mchawla@worldbank.org)>; Rocio Schmunis <[rschmunis@worldbank.org](mailto:rschmunis@worldbank.org)>; Adrienne Kate Mcmanus <[amcmanus@worldbank.org](mailto:amcmanus@worldbank.org)>; Gabrielle Lynn Williams <[gwilliams1@worldbank.org](mailto:gwilliams1@worldbank.org)>; WB Health Events <[wbhealthevents@worldbank.org](mailto:wbhealthevents@worldbank.org)>; Muhammad Ali Pate <[mpate@worldbank.org](mailto:mpate@worldbank.org)>

**Subject:** Invitation to the Consultation on Financing Coronavirus Disease 2019 (COVID-19) Vaccine Development | Thursday, February 20, 2020 | 9:30am to 1:30pm | World Bank Headquarters, Washington DC

Dear Dr. Fauci,

On behalf of the World Bank health team, in coordination with the Coalition for Epidemic Preparedness Innovations (CEPI), it is our pleasure to invite you to a half-day consultation on **Financing Coronavirus Disease 2019 (COVID-19) Vaccine Development**. The meeting is set to take place on **Thursday, February 20, 2020** from **9:30am to 1:30pm** at the **World Bank Offices in Washington DC** (located at 1818 H St NW) on **floor C2, conference room MC C2-125**.

As you know, the novel Coronavirus outbreak, which started in Wuhan, China, is evolving rapidly. As of today, the number of confirmed cases has increased significantly to over 60,000 and the virus has reached 25 countries. The outbreak, a Public Health Emergency of International Concern (PHEIC), poses a threat to countries worldwide, especially those with weak health systems and low levels of pandemic preparedness.

It is of urgent importance that we move quickly to finance the development of the appropriate countermeasures for a disease that risks becoming endemic across the globe. Two critical issues are necessary to address: i) immediate financing for the development and scale-up of a diversified portfolio of vaccines, and ii) financing the manufacturing and procurement of vaccine for global distribution.

To enhance our discussions we are working on a background paper which we will share along with an agenda at the earliest. Recognizing the short notice, we will provide remote connection details for those unable to travel for the meeting. A working lunch will also be provided.

We hope that you will be able to participate in this important meeting. Kindly confirm your participation to Ms. Gabrielle Williams, Health, Nutrition and Population Global Practice, World Bank ([wbhealthevents@worldbank.org](mailto:wbhealthevents@worldbank.org)). Please do not hesitate to reach out with any questions.



Looking forward to your positive response.

Best regards,  
Feng Zhao

**From:** Fauci, Anthony (NIH/NIAID) [E]  
**Sent:** Wed, 19 Feb 2020 16:16:33 +0000  
**To:** Conrad, Patricia (NIH/NIAID) [E]  
**Subject:** FW: Potential Speaking Engagement: Winter 2021

Please RSVP sorry no. Too busy.

**Anthony S. Fauci, MD**  
Director  
National Institute of Allergy and Infectious Diseases  
Building 31, Room 7A-03  
31 Center Drive, MSC 2520  
National Institutes of Health  
Bethesda, MD 20892-2520  
Phone: (b) (6)  
FAX: (301) 496-4409  
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

---

**From:** Andrew Turley (b) (6)  
**Sent:** Wednesday, February 19, 2020 10:26 AM  
**To:** Fauci, Anthony (NIH/NIAID) [E] (b) (6) >  
**Cc:** Andrew Turley (b) (6) >  
**Subject:** Potential Speaking Engagement: Winter 2021

Dear Dr Fauci

I know things must be impossibly busy right now with the current coronavirus issues but wanted to touch base to see whether you may be interested in a speaking engagement next Spring as part of our

(b) (6)  
(b) (6)

A bit about me: I am a (b) (6) Air Force Major General and retired SES from the Department of Defense.

(b) (6)

(b) (6) is an associate professor emeritus from the School of Medicine and Health Sciences at the George Washington University. We are both longtime admirers.

(b) (6) consists of people drawn from a wide variety of backgrounds, including doctors, lawyers and many from the senior tiers of the finance and corporate worlds up to and including former CEOs and other executives (and even a few retired senior government folks like me). It is an active, well-read and learned community with a keen interest in current events. As an example, we have a very active Foreign Policy Association chapter that always draws folks from across the spectrum of political and policy perspectives for interesting and well-informed discussions.

Our (b) (6) speaker series consists of presentations on a vast array of subjects, from literature and art to current events and public policy issues. Typically held on Tuesdays nights from December through April, these sessions consist of a presentation of an hour or so followed by Q&A and general discussion. We always draw standing room only crowds.

Recent and upcoming speakers have included:



The recent coronavirus outbreak has captured the interest of the nation and the world. Our folks would be extremely interested in how organizations such as NIH respond and address these incredible challenges. A presentation by you about your work on these issues, from your groundbreaking work on AIDS onward or any other topic of your choosing, would be absolutely the height of our season.

We pay transportation, lodging, an honorarium, and could even arrange for a round of golf at one of our outstanding golf courses! (Of equal importance is that we can offer you a brief respite from the cold of winter.). There are direct flights from Washington DC to West Palm Beach. We have openings in January, February and March 2021.

We would be deeply appreciative of your favorable consideration. Please feel free to contact me if I can answer any questions

F. ANDREW TURLEY

CELL: (b) (6)  
HOME: (b) (6)



**From:** Fauci, Anthony (NIH/NIAID) [E]  
**Sent:** Wed, 19 Feb 2020 14:42:50 +0000  
**To:** Greg Folkers ([REDACTED] (b) (6))  
**Subject:** FW: Clip of Dr. Fauci on NPR

Good interview on NPR. Possible for Director's Page.

**Anthony S. Fauci, MD**  
Director  
National Institute of Allergy and Infectious Diseases  
Building 31, Room 7A-03  
31 Center Drive, MSC 2520  
National Institutes of Health  
Bethesda, MD 20892-2520  
Phone: [REDACTED] (b) (6)  
FAX: (301) 496-4409  
E-mail: [REDACTED] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

---

**From:** Lindsey Beall <lbeall@scgcorp.com>  
**Sent:** Wednesday, February 19, 2020 8:22 AM  
**To:** Deatrick, Elizabeth (NIH/NIAID) [C] [REDACTED] (b) (6)>; Pekoc, Ken (NIH/NIAID) [E] [REDACTED] (b) (6); Conrad, Patricia (NIH/NIAID) [E] [REDACTED] (b) (6); Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6)>; Doepel, Laurie (NIH/NIAID) [E] [REDACTED] (b) (6); Folkers, Greg (NIH/NIAID) [E] [REDACTED] (b) (6); Hoffman, Hillary (NIH/NIAID) [E] [REDACTED] (b) (6); Oplinger, Anne (NIH/NIAID) [E] [REDACTED] (b) (6); Rancourt, Anne (NIH/NIAID) [E] [REDACTED] (b) (6); Lavelle, Judith (NIH/NIAID) [E] [REDACTED] (b) (6); Leifman, Laura (NIH/NIAID) [E] [REDACTED] (b) (6)>; Stover, Kathy (NIH/NIAID) [E] [REDACTED] (b) (6)>; Routh, Jennifer (NIH/NIAID) [E] [REDACTED] (b) (6)>; NIAID OD AM <NIAIDODAM@niaid.nih.gov>; Awwad, David (NIH/NIAID) [C] [REDACTED] (b) (6)  
**Cc:** Osvald, Maria <mosvald@scgcorp.com>; Fabry, Cynthia (NIH/NIAID) [E] [REDACTED] (b) (6); Meylin Correa <mcorrea@scgcorp.com>; Marcia Bache <mbache@scgcorp.com>; Megan Schartner <MSchartner@scgcorp.com>  
**Subject:** Clip of Dr. Fauci on NPR

Good morning,

Below is a clip of Dr. Fauci discussing coronavirus on NPR's Morning Edition. This clip aired earlier this morning.

[https://app.criticalmention.com/app/#/clip/public/1b0da123-0cd7-4012-90a6-b82d27c73191?show\\_sentiment=false](https://app.criticalmention.com/app/#/clip/public/1b0da123-0cd7-4012-90a6-b82d27c73191?show_sentiment=false)

Thanks,

Lindsey

---

**From:** Critical Mention <[do-not-reply@criticalmention.com](mailto:do-not-reply@criticalmention.com)>

**Sent:** Wednesday, February 19, 2020 8:18 AM

**To:** Lindsey Beall

**Subject:** Critical Mention: Megan Schartner has shared a Radio Mention with you



You're always on it with Critical Mention.

***Megan Schartner* has shared a Radio  
Mention with you!**

**From** Megan Schartner ([mschartner@scgcorp.com](mailto:mschartner@scgcorp.com))

## [View Mention](#)

[No Program Name Available](#)



### Radio

**Program Name** No Program Name Available

**Source** WLRNFM

**Market** DMA: 16 Miami, FL

**Time** Feb 19, 2020 8:07 AM EST

**Clip Length** 07:16.852

it's morning edition from n. p. r. news on david green in culver city california and a militant in washington d. c. good morning in china the death toll from the corona virus has hit two thousand world leaders in public health officials are trying to contain it but new infections keep showing up carl golden for example he was a passenger on the diamond princess that's the cruise ship where hundreds of people got the virus we took an aquatic clues to also alone what went wrong who knew we were going and the crew and beautiful omar here's how he ended up in omaha carl his wife jerry were quarantined on that ship for twelve days in a felt fine the whole time but then the gun on a flight back to the u. s. and carl started feeling sick or wind burke from japan to this day about two hours into the flight they woke up with a high fever after napping a little bit and the doctors on board confirmed the and then on the flight landed he tested positive for the coronavirus he's recovering now in a bio contain mean unit at the university of nebraska's medical center he's going to have to spend fourteen days there and isolation well you know working %hesitation %hesitation catering we've heard on a but one of the two days of the different doctors each day i



didn't have a clue but got a little cough still you can you might want to debate left me and i'm a little to keep but maybe also because of the jet lag in the travels and everything else on top of it no it doesn't feel any different than you know recuperating from a regular coal carl's wave jerry hasn't been diagnosed with the virus is she's being monitored in a different part of the hospital but their case is a good example of some things we know and some things we don't know about how this virus is spreading so we have called doctor anthony **fauci** he's director of the national institute of allergy and infectious diseases good morning sir good morning so carl coleman was fine all those days on the ship then he gets on a plane and he gets a fever what does that tell us about how this virus is spreading well the virus has the ability to bind it to certain cells in your body particularly in your lung so you can get anything from miles a symptomatic illness to a cough and a fever to some people about oh about twenty percent of the people come to the attention of medical than physicians in health care providers can get serious pneumonias requiring intensive care it sounds like this individual is on the %hesitation mild side of the illness because as he said it doesn't feel much more than just a common cold and as a matter of fact corona viruses in general prior to this all one of the causes of the common cold okay so what does that tell us i mean bleary often looking at the cases we're looking at a rising death toll which is tragic we look much less at the people like carly say you know my voice is raspy a had a fever had a cough the years a wide range of stuff symptoms with this virus did do we know why some people seem to be doing okay and other people are getting hit really hard well whether a couple things about that for the first thing is that any any kind of viral infection or any pathogen infection there's always a wide range of responses in the sense almost like a bell shaped curve some people get no sim is at all and we do have a symptomatic corona virus infection with this particular episode and then there's the bulk of people who get some sort of symptoms and then a small percentage of people do really really very poorly now that relates to the ability of the body to handle the virus and the one thing we know when it's not unique to this virus is that the elderly those with underlying conditions like chronic heart disease lung disease diabetes obesity they tend to get more complications much more than for example and otherwise healthy individual and that's the reason why if you look at the death rate which is around two percent for this disease at this time it is disproportionately high are among the elderly and particularly those who have underlying conditions this is interesting question carlin is wave terry presumably they work together the entire time they were quarantined right and if he gets the virus she does not did she just get lucky do some people have some sort of immune undefended don't it's a combination that's a good question it's a combination of both there is no virus that has one hundred percent attack rate even the most of infectious of all viruses like measles doesn't get a hundred percent of of %hesitation vulnerable people but respiratory viruses particularly things like influenza or the corona virus the attack rate is burying percentage and it was if he was really likely that his wife i don't think she necessarily had any on the line immune protection though that's possible the maybe some cross reaction of immune protection with other %hesitation microbes that she came into contact with but in most likely is as you suggest the luck of the draw okay interesting

and they got to patching wondered if you could clear something up because we've been hearing reports about so called super spread ours these you who spread the virus to a very high a number of other people and it sounds like a scary thing but and i just under is this a real phenomenon there that there are people who give the virus to more people than most and why is that happening well it is certainly the phenomenon of the super spreading israel we story with sars back in two thousand two and two thousand in three and they're episodes already with this particular new corona virus and it's a combination of two things it's an individual whose either at a particular moment in time shedding a very large amount of virus which makes it much easier to infect a group of people who are around him but you also see it sometimes in the hospital setting when you have a number of health care providers taking care of someone and that person is shedding a lot of virus so the short answer to your question is there are super spread is and it's a real phenomenon okay okay what we would you say at this moment is the most important or the most pressing question about this virus that we don't have answers to yet well what we don't know for sure we know that there are people who are infected will without symptoms or very minimal symptoms they hardly notice they're infected well we don't know is the extent to which people who have no symptoms are spreading it so we do know that this can occur because we have anecdotal documented cases of people who do not have symptoms who actually have infected someone usually a family member but we don't know the extent to which this cars in the broad component of this outbreak doctor anthony **fauci** the director of the national institute of allergy and infectious diseases sir thanks for joining us it was a pleasure to be with you

---

Critical Mention allows users to search global TV, Radio, Online News & Social from the United States, Canada, and Europe, watch video, edit and share coverage, receive real-time email alerts, build reports, and analyze coverage through word clouds and graphs.

Want to learn more about Critical Mention? Sign up for a demo [here](#).

Copyright © 2020 Critical Mention. All rights reserved.

**Our mailing address is:**

Critical Mention

521 5th Avenue

16th Fl

New York, NY 10175



**From:** Fauci, Anthony (NIH/NIAID) [E]  
**Sent:** Wed, 19 Feb 2020 13:03:08 +0000  
**To:** bdoherly@mms.org  
**Cc:** lbaden@nejm.org;Fauci, Anthony (NIH/NIAID) [E];Redfield, Robert R. (CDC/OD);Lane, Cliff (NIH/NIAID) [E];Eisinger, Robert (NIH/NIAID) [E]  
**Subject:** RE: New England Journal of Medicine Editorial  
**Attachments:** H. Clifford Lane's ICMJE-2013 - For Coronavirus Editorial Fauci et al -.pdf

Briana:

Cliff Lane has separately sent his signed CTA. I am attaching his ICMJE Form. And so you should have all the forms for all 3 authors: Fauci, Lane, and Redfield. Please let me know if you have any questions.

Best regards,

Tony

Anthony S. Fauci, MD  
Director  
National Institute of Allergy and Infectious Diseases  
Building 31, Room 7A-03  
31 Center Drive, MSC 2520  
National Institutes of Health  
Bethesda, MD 20892-2520  
Phone: (b) (6)  
FAX: (301) 496-4409  
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

-----Original Message-----

From: Briana Doherty <onbehalf@manuscriptcentral.com>  
Sent: Monday, February 10, 2020 11:11 AM  
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>  
Cc: lbaden@nejm.org  
Subject: New England Journal of Medicine Editorial

Dear Dr. Fauci,

I am delighted that you have agreed to write a signed editorial to accompany the article on the initial estimates of key transmission parameters associated with nCoV-2019 virus by Li et al.

The general purpose of the Journal's editorials is to provide the reader with an authoritative interpretation or elaboration based on the substance of the article. Since this substance is usually not within the average reader's special competence, such readers will particularly benefit if the editorial avoids technical jargon, explains the article's contribution to a field of knowledge, and emphasizes, whenever possible, its clinical implications. The editorial commentary should not be concerned exclusively with the article in question but rather should use the article as a starting point for a more general discussion.

Because editorials involve interpretation and opinion, you and your potential coauthor must be free of significant relevant financial associations (including equity interest, regular consultancies, or major research support) with a company, or with a competing company, that stands to gain from the use of a product discussed in the editorial. Please contact me immediately if you are considering a coauthor, so I can ensure that your candidate meets our

criteria. Additional information about disclosure of financial and other associations appears below this letter.

Please bear in mind that your editorial represents your (and any coauthor's) personal opinion. The Journal does not include statements of grant or other support or acknowledgments with editorials.

Journal policy dictates that we must have on file a signed Copyright Transfer and Authorship Agreement from each author before a manuscript can be accepted. Therefore, the enclosed form should be signed by all authors and faxed to (781) 207-6529.

Your editorial is due at the Journal on Monday, February 17, at the very latest if the deadline imposed by our printing schedule is to be met. If the editorial is to include a figure, please submit the figure at least one week before the due date for the editorial itself.

\*\*\* Additional information about preparing and submitting your editorial is given below; please read it carefully. \*\*\*

The editors must reserve the right to edit (or even reject) your editorial, but whether we use it or not, the Journal currently offers a modest stipend of \$300.

Thanks again for agreeing to write this editorial for the Journal. I look forward to receiving it.

Sincerely yours,

Lindsey R. Baden, M.D.  
Deputy Editor

New England Journal of Medicine  
10 Shattuck Street  
Boston, MA 02115  
(617) 734-9800  
Fax: (617) 739-9864  
<http://www.nejm.org>

#### LENGTH OF YOUR EDITORIAL

NEJM editorials should not exceed two printed pages. This means that your word count before editing should not exceed 750 words (approximately 4500 characters). Note that we spell out trial names and most other abbreviations for our readers, and we include trial registration numbers for any clinical trials mentioned; these will lengthen your editorial if you have not included them. Please provide a title not exceeding 45 characters and a word count for the text; the entire manuscript, including references, should be double-spaced.

#### REFERENCES

Cite no more than 10 references, including the article you are writing about. The average collection of 10 references requires about a quarter of a printed page.

#### TABLE OR FIGURE

A table or a figure in your editorial will require a reduction in the number of words; because figures and tables vary in size, you may be asked to shorten the text of your editorial during the production process. A quarter-page table roughly equals 250 words, and a half-page table roughly equals 500 words.

#### DISCLOSURES

When completing your disclosure form, please indicate, in the "Comments" field next to the type of relationship being disclosed, the amount (in U.S. dollars) of any support you have received. Please also indicate how much of this support has been received over the past 2 years. Please e-mail your completed disclosure form to [editorial@nejm.org](mailto:editorial@nejm.org).

In the event of publication, each author's submitted disclosure form will be posted on the Web (with any dollar amounts redacted).

#### COPYRIGHT TRANSFER

Each author must complete a copyright transfer agreement form. Please sign it and fax it back to 781-207-6529 as soon as possible.

#### TO SUBMIT YOUR EDITORIAL

\*\*\* It is important that you follow the instructions below to ensure that your article enters the correct queue. \*\*\*

When you are ready to submit your manuscript, please log in to the New England Journal of Medicine - Manuscript Central site (<http://mc05.manuscriptcentral.com/nejm>). Your case-sensitive USER ID is [afauci@niaid.nih.gov](mailto:afauci@niaid.nih.gov). For security purposes, your password is not listed in this message. If you are unsure of your password, please visit <https://mc05.manuscriptcentral.com/nejm> and enter your e-mail address in the "Forgot Your Password?" field.

Once you are logged in, the Main Menu will be displayed. Please click on the Author Center, where you will find the manuscript listed under "Invited Manuscripts." You can click on the "Continue Submission" button to begin submitting your article.



# Please wait...

If this message is not eventually replaced by the proper contents of the document, your PDF viewer may not be able to display this type of document.

You can upgrade to the latest version of Adobe Reader for Windows®, Mac, or Linux® by visiting [http://www.adobe.com/go/reader\\_download](http://www.adobe.com/go/reader_download).

For more assistance with Adobe Reader visit <http://www.adobe.com/go/acrreader>.

Windows is either a registered trademark or a trademark of Microsoft Corporation in the United States and/or other countries. Mac is a trademark of Apple Inc., registered in the United States and other countries. Linux is the registered trademark of Linus Torvalds in the U.S. and other countries.

**From:** Fauci, Anthony (NIH/NIAID) [E]  
**Sent:** Wed, 19 Feb 2020 12:37:58 +0000  
**To:** Jon LaPook  
**Subject:** RE: Coronavirus

It means that you are an outstanding and committed journalist. 😊

Anthony S. Fauci, MD  
Director  
National Institute of Allergy and Infectious Diseases  
Building 31, Room 7A-03  
31 Center Drive, MSC 2520  
National Institutes of Health  
Bethesda, MD 20892-2520  
Phone: (b) (6)  
FAX: (301) 496-4409  
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

-----Original Message-----

**From:** Jon LaPook (b) (6)  
**Sent:** Wednesday, February 19, 2020 7:36 AM  
**To:** Fauci, Anthony (NIH/NIAID) [E] (b) (6)  
**Subject:** Re: Coronavirus

Got it. What does it mean that I'm waking up thinking about coronavirus?  
:)

Jonathan LaPook, M.D.  
Chief Medical Correspondent, CBS News  
Professor of Medicine

NYU Langone Health  
Twitter @DrLaPook

On Feb 19, 2020, at 7:33 AM, Fauci, Anthony (NIH/NIAID) [E]

(b) (6) wrote:

Jon:

Your hypothesis is certainly possible, but I think unlikely. In a NEJM paper for which I have just written an editorial, there were 400+ patients and none younger than 15 years old. I am certain that children from birth to 15 years were exposed to and primed by coronaviruses multiple times and so if 2nd infection enhancement were an important issue, we should have seen it in children and adolescents 15 years old and younger. Just a thought, but anything is possible.

Best,  
Tony

Anthony S. Fauci, MD  
Director

National Institute of Allergy and Infectious Diseases Building 31, Room 7A-03  
31 Center Drive, MSC 2520  
National Institutes of Health  
Bethesda, MD 20892-2520

Phone: (b) (6)

FAX: (301) 496-4409

E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

-----Original Message-----

From: Jon LaPook (b) (6)

Sent: Wednesday, February 19, 2020 7:26 AM

To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)



Subject: Coronavirus

Good morning, Tony,

I woke up thinking this: given the relative sparing of young people during the COVID-19 outbreak, could something similar to what happens with dengue be going on? Could a second coronavirus infection - albeit with a genetically different variant than the first - bring about worse disease than the first? And, since up to a third of the common cold is caused by a variant of coronavirus, could older people somehow have been primed by an earlier coronavirus infection?

Jon

Jonathan LaPook, M.D.  
Chief Medical Correspondent, CBS News  
Professor of Medicine  
NYU Langone Health  
Twitter @DrLaPook

**From:** Fauci, Anthony (NIH/NIAID) [E]  
**Sent:** Wed, 19 Feb 2020 03:41:52 +0000  
**To:** Grigsby, Garrett (HHS/OS/OGA);Redfield, Robert R. (CDC/OD);Cetron, Marty (CDC/DDID/NCEZID/DGMQ)  
**Cc:** Billet, Courtney (NIH/NIAID) [E]  
**Subject:** FW: Todays report from Dr Iwata From Kobe univ on Diamond Princess SHIP COVID-19

Folks:

You should take a look at this video (see link). The person, who is a Japanese infectious diseases specialist, is a bit inarticulate in the beginning of the video, but he provides a vivid and disturbing description of the conditions on the Diamond Princess.

Tony

**From:** Larry Washburn <[REDACTED] (b) (6)>  
**Sent:** Tuesday, February 18, 2020 9:43 PM  
**To:** Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6)>  
**Cc:** Hodes, Richard (NIH/NIA) [E] [REDACTED] (b) (6)  
**Subject:** Todays report from Dr Iwata From Kobe univ on Diamond Princess SHIP COVID-19

Dr. Fauci,

I am living in Japan [REDACTED] (b) (6) and this morning I saw this video released by Dr. Kentaro Iwata a infectious disease control specialist

Please have somebody on your staff review this **ASAP** short description of Dr Iwata's 1 day visit on the ship. He has experience with Ebola, Sars etc. He describes an alarming condition that you and CDC must be aware of. Japan has no CDC and they tend to be very bureaucratic.

<https://www.youtube.com/watch?v=vtHYZkLuKcl&feature=youtu.be>

I apologize if you already have this information.

Respectfully  
Larry Washburn [REDACTED] (b) (6) Living in Japan

**From:** Fauci, Anthony (NIH/NIAID) [E]  
**Sent:** Wed, 19 Feb 2020 01:32:37 +0000  
**To:** Conrad, Patricia (NIH/NIAID) [E]; NIAID OD AM  
**Subject:** RE: CROI COVID-19 Session; Tuesday March 10 lunch

I am not that excited about doing this. They have CDC doing the Epi, which is fun. They have Ralph Baric doing the virology, which I easily can do, and they have me talking about what NIAID is doing, which is important, but boring from a lecture standpoint.

Greg:

What say you?

---

**From:** Conrad, Patricia (NIH/NIAID) [E] (b) (6) >  
**Sent:** Tuesday, February 18, 2020 8:22 PM  
**To:** NIAID OD AM <NIAIDODAM@niaid.nih.gov>  
**Subject:** Fwd: CROI COVID-19 Session; Tuesday March 10 lunch

Sent from my iPhone

Begin forwarded message:

**From:** Donna Jacobsen <djacobsen@iasusa.org>  
**Date:** February 18, 2020 at 8:18:06 PM EST  
**To:** "Fauci, Anthony (NIH/NIAID) [E]" (b) (6) >  
**Cc:** "Conrad, Patricia (NIH/NIAID) [E]" (b) (6), "Elaine J. Abrams, MD" (b) (6), "Sharon Hillier PhD" (b) (6), "Hoxie, James" (b) (6) >, "Benson, Connie" (b) (6), "Kevin Bowen" (b) (6) >  
<kbowen@iasusa.org>  
**Subject:** RE: CROI COVID-19 Session; Tuesday March 10 lunch

(resending with Patty's correct email address)

Dear Dr Fauci:

As I mentioned on the phone, we just today decided that we will have a special session on COVID-19 at CROI. It will be on Tuesday, March 10, during the lunch break; the initial general structure will be a 10- to 15- minute overview of the epidemic (CDC), a 25-min talk by Ralph Barac (UNC) about the virology of coronaviruses, and a 10- to 15-minute summary on what NIAID/NIH is doing and planning. We thought that this being one of the first large medical conferences in infectious diseases this year, that it is important that we address COVID 19 at CROI.



We know that this is terribly last minute, but the CROI Chairs and Foundation are hoping you are free to give the NIAID/NIH update. CROI is in Boston, March 8 to 11.

If you think you would be able to do this, we will send a more formal communication with details and work with Patty on the specifics. Thank you so much Dr Fauci; we hope you will be able to join us.

Best,

Donna

Donna M. Jacobsen  
Executive Director/President  
International Antiviral (formerly AIDS) Society-USA  
131 Steuart St, Ste 500  
San Francisco, CA 94105  
415-544-9400

<https://www.iasusa.org>



**About IAS–USA:** Established in 1992, the IAS–USA is a not-for-profit, professional education organization. The mission of the IAS-USA is to improve the prevention, treatment, care, and quality of life for people with or at risk of HIV, hepatitis C virus, or other viral infections through high-quality, relevant, balanced, and needs-oriented education and information for practitioners who are actively involved in medical care. The organization's educational activities are particularly intended to bridge clinical research and patient care.

**Confidentiality Notice:** This e-mail and its attachments may contain privileged and confidential information intended solely for the use of the IAS-USA and the recipient(s) named above. If you are not the intended recipient, or the employee or agent responsible for delivering this message to the intended recipients, you are hereby notified that any review, dissemination, distribution, printing, or copying of this e-mail message and/or any attachments is strictly prohibited. If you have received this transmission in error, please notify the sender immediately and permanently delete this e-mail and any attachments.

**From:** Fauci, Anthony (NIH/NIAID) [E]  
**Sent:** Wed, 19 Feb 2020 00:28:47 +0000  
**To:** Retzlaff, Jon  
**Subject:** RE: ACTION: Invitation to Provide Opening Remarks at the NIH-AACR Cancer, Autoimmunity, and Immunology Conference on March 23rd (on the NIH campus)

Not interested right now. Too busy. Have Hugh or someone else do this.

**Anthony S. Fauci, MD**  
**Director**  
**National Institute of Allergy and Infectious Diseases**  
**Building 31, Room 7A-03**  
**31 Center Drive, MSC 2520**  
**National Institutes of Health**  
**Bethesda, MD 20892-2520**  
**Phone:** (b) (6)  
**FAX:** (301) 496-4409  
**E-mail:** (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

---

**From:** Retzlaff, Jon <jon.retzlaff@aacr.org>  
**Sent:** Sunday, February 16, 2020 6:12 PM  
**To:** Fauci, Anthony (NIH/NIAID) [E] (b) (6)>  
**Cc:** Barasch, Kimberly (NIH/NIAID) [C] (b) (6)>; Conrad, Patricia (NIH/NIAID) [E] (b) (6)>

**Subject:** ACTION: Invitation to Provide Opening Remarks at the NIH-AACR Cancer, Autoimmunity, and Immunology Conference on March 23rd (on the NIH campus)

Dear Dr. Fauci,

It's pretty clear that you have been ridiculously busy over the past month+ serving as our nation's top infectious disease doctor! Thanks so much for your leadership and dedication, Dr. Fauci!

I'm actually reaching out to you on a topic other than the coronavirus, as I am writing on behalf of the co-chairs for an important NIH-American Association for Cancer Research (AACR) conference (**the NIH-AACR Cancer, Autoimmunity, and Immunology Conference**) that will **be taking place on March 23-24, 2020, on the NIH campus (in the Masur Auditorium in the NIH Clinical Center).**

The co-chairs would like to invite you to be the opening speaker on Monday, March 23<sup>rd</sup>. Dr. Sharpless will be the opening speaker on Tuesday, March 24<sup>th</sup>. Please see the attached draft agenda.



Now in its third year, the Cancer, Autoimmunity, and Immunology Conference focuses on: 1) understanding the biology of immune-related adverse events which have occurred in cancer patients treated with immunotherapies and how that might inform the study of autoimmune disease, and 2) defining the potential for the study of autoimmune disease to lead to greater understanding of the treatment and management of immune-related adverse events during and following cancer therapies. The goal of this interdisciplinary conference is to bring together people who might not typically interact to promote cross-fertilization for the betterment of both research and clinical care, which is why there are four NIH ICs very much involved in the Conference, including: NCI, NIAID, NIAMS, and NIDDK.

Chairing this effort on behalf of the AACR is Julie R. Brahmer, MD, Johns Hopkins University. From the NIH, we have Elad Sharon, MD, MPH, NCI; Ravi Madan, MD, NCI; Connie Sommers, PhD, NCI; Howard Young, PhD, NCI; Katarzyna Bourcier, PhD, NCI; Marie Mancini, PhD, NIAMS; Annette Rothermel, PhD, NIAID; and Lisa Spain, PhD, NIDDK.

I know the diverse audience, including patients, researchers, clinicians, industry, regulators, and others, would be thrilled by your presence. Of course, we also know that you have participated in the previous two conference on this topic, which underscores why they would love to have you participate again!

Please let us know at your earliest convenience if you are interested and able to participate in the conference on Monday, March 23rd. If you have additional questions or concerns, you can contact me at [jon.retzlaff@aacr.org](mailto:jon.retzlaff@aacr.org) or (b) (6)

Thanks again, Dr. Fauci, and I look forward to hearing from you!

Jon

**Jon Retzlaff, MBA, MPA**

CHIEF POLICY OFFICER  
VICE PRESIDENT, SCIENCE POLICY AND GOVERNMENT AFFAIRS  
Office of Science Policy and Government Affairs



American Association for Cancer Research  
1401 H Street, NW, Suite 740 | Washington, DC 20005

202-898-6499 Direct | 267-765-1087 Fax | (b) (6) Cell

[jon.retzlaff@aacr.org](mailto:jon.retzlaff@aacr.org) | [www.AACR.org](http://www.AACR.org)



Please note that this e-mail and any files transmitted with it may be privileged, confidential, and protected from disclosure under applicable law. This information is intended only for the person or entity to which it is addressed and may contain confidential or privileged material. Any review,



---

retransmission, dissemination, or other use of, or taking of any action in reliance upon, this information by persons or entities other than the intended recipient is prohibited. If you received this in error, please contact the sender and delete the material from any computer.